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ABSTRACT 
Aberrant methylation of 5' CpG islands is one of the major mechanisms for 
tumor suppressor gene silencing in human malignancies. To identify novel 
cancer-related genes in multiple myeloma (MM), we carried out a genome-wide 
search for aberrantly methylated CpG islands, using methylation-sensitive arbitrarily 
primed polymerase chain reaction (MS.AP-PCR) on four M M cell lines, five primary 
M M samples and three normal peripheral blood samples. Sequencing analysis of the 
48 differentially methylated sequences revealed that 16 of them were 
transcript-associated CpG islands, of which 13 of them were known genes and three 
were putative novel genes. We further examined two potential cancer-related genes 
zinc fingers and homeoboxes {ZHX2) and ring finger protein 180 (RNFJ80). Of the 
five M M cell lines (RPMI-8226, U266, OPM-2, NIC-H929 and LPl ) , aberrant 
promoter hypermethylation of ZHX2 was detected in two cell lines (U266 and 
OPM-2). Transcriptional silencing and down-regulation was demonstrated in the 
methylated U266 and OPM-2 cell lines, respectively, and reactivation occurred in the 
non-expressing U266 cell line after demethylation treatment. Besides, aberrant 
promoter methylation of 5'CpG island of a novel gene RNF180 occurred in 63 % 
(15/24) primary M M tumors and three out of five M M cell lines (U266, OPM-2 and 
NCI-H929). Using semi-quantitative RT-PCR and bisulfite sequencing analysis, we 
demonstrated a correlation between RNF180 hypermethylation and its gene silencing. 
RNF180 mRNA was absent in the three cell lines (U266, OPM-2 and NCI-H929) 
with densely methylated alleles. Treatment of RNF180 methylated and 
non-expressing cell lines with demethylating agent, 5'-aza-2'-deoxycytidine, 
reactivated its expression in two cell lines (OPM-2 and NCI-H929). These results 
demonstrated the use of MS.AP-PCR in the identification of novel 
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methylation-regulated genes and suggested that hypermethylation-induced silencing 





















因 表 達 缺 失 的 基 因 和 灭 可 能 與 多 發 性 骨 髓 瘤 的 發 生 發 展 相 關 。 
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CHAPTER 1 GENERAL INTRODUCTION 
Multiple myeloma (MM) is a clonal plasma cell-derived malignancy that 
accounts for almost 10 % and ranks second in prevalence among all hematologic 
malignancies. The development of M M is characterized by a multi-step process, 
from benign monoclonal gammopathy of undetermined significance through 
asymptomatic myeloma to the familiar entity of symptomatic MM. This biological 
process involves multiple genetic changes such as inactivation of tumor suppressor 
genes (Gonzalez et al, 2000) and activation of oncogenes (Fabris et al, 2005) that 
are driven by an ongoing genomic instability (Sawyer et al” 2005). However, the 
underlying genetic mechanisms of M M development remain largely unclear. 
Aberrant promoter methylation is an emerging epigenetic mechanism causing 
inactivation of cancer-related genes. It plays an important role in human 
carcinogenesis. To date, around forty PubMed journals have reported methylation 
changes in M M , but only ten of them have demonstrated a correlation of aberrant 
methylation with down-regulation of the cancer-related genes. Many of these 
methylation analyses targeted on specific candidate genes as profiling studies (Chim 
et al, 2004; Galm et al, 2004; Takahashi et al, 2004). These investigations require 
prior information on the DNA sequence and are often limited to known 
cancer-related genes. Conversely, the use of genome-wide scanning approaches to 
assess global methylation changes require no prior sequence information and allows 
identification of novel genes involved in M M tumorigenesis. 
The objective of this study was to identify CpG islands with altered DNA 
methylation patterns in M M using a genome-wide scanning approach called 
methylation sensitive arbitrarily primed polymerase chain reaction (Gonzalgo et al, 
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1997). The methylation status of 5'CpG island of identified candidate genes and their 
expression were investigated by combined bisulfite restriction analysis and 
semi-quantitative RT-PCR, respectively. The relationship between DNA methylation 
and transcriptional silencing was further examined using demethylation treatment, 
which could restore gene transcription in non-expressing cells with dense 
methylation. 
In summary, our findings demonstrate that genome-wide DNA methylation 
studies enable us to identify novel methylation-regulated genes, providing a 
platform to gain insights into the involvement of these genes in M M tumorigenesis. 
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CHAPTER 2 LITERATURE REVIEW 
2.1 Multiple myeloma 
M M is a clonal plasma cell-derived hematologic malignancy characterized by 
unregulated proliferation of monoclonal plasma cells. These cells accumulate in the 
bone marrow and secret monoclonal immunoglobulins and cytokines, which cause 
decreased bone marrow function and destruction of bone tissue. Patients with M M 
usually present with bone pain related to lytic bone lesions, frequent anaemia and 
renal impairment. 
• ‘ 、mLm H M ^ t J L i ^ 
Figure 2.1 M M cells. A smear of bone marrow aspirate from a patient with MM. 
Note that there are numerous plasma cells with eccentric nuclei and a perinuclear 
halo of clearer cytoplasm. (Adapted from the website: 
http://www-medlib.med.utah.edu/WebPath/HEMEHTML/HfiME042.html) 
2.2 Epidemiology of MM 
M M accounts for almost 10% of all hematologic cancers and is the second most 
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prevalent hematologic malignancy after non-Hodgkin's lymphoma. It was estimated 
that there were 15,270 cases and 11,070 deaths of myeloma in 2004 in the United 
States, reflecting a high mortality rate (Jemal et al, 2004). The 5-year survival rate 
was only 28 % (Dalton et al, 2001). In general, the median age at diagnosis is 65 
years, and only 2 % of cases are diagnosed in people under the age of 45 (Angtuaco 
et al, 2004). M M affects men more frequently than women (Cartwright et al, 2002), 
and its incidence is higher in African and lower in Asian population relative to 
Caucasians (Zaidi and Vesole, 2001). It accounts for only one to two cases per 
100,000 people of the Asian population. 
In Hong Kong, the incidence rate for M M was 1.78 per 100 000 population 
(Chow et al., 2003). According to the statistics from the Hong Kong Hospital 
Authority in 2002, the median age at presentation was 74，with frequency increases 
with age. The ratio of M M incidence in men and women was 1.7: 1. The mortality 
rate for men and women was 84 % and 67 %, respectively, accounting for almost 1 
% of all cancer deaths in Hong Kong. 
2.3 Risk factors 
The exact cause of M M remains unknown. Environmental factors including 
chemical and radiation exposure have been associated with an increased risk in 
developing M M (George and Sadovsky, 1999). Prolonged exposure o f pesticides or 
herbicides and chronic antigenic stimulation may also be the risk factors for M M 
(Angtuaco et al” 2004; Zaidi and Vesole, 2001). However, in most cases, individuals 
who develop M M have no clear risk factors and its development may be the result o f 
various factors acting together. 
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2.4 Pathophysiology of MM 
Mature plasma cells normally make up less than 5 % of bone marrow cellularity. 
Their precursors are plasmablasts or B lymphocytes that migrate to the marrow from 
the lymph nodes in response to antigen stimulation and cytokines released from 
helper T cells in the lymph node. In the bone marrow, the precursor cells stop 
proliferation and differentiate into mature plasma cells. Normal plasma cells produce 
antibodies (or immunoglobulins) that are essential to our humoral immunity. These 
immunoglobulins are released in response to foreign antigen exposure and include 
IgG, IgA, IgM, IgD, and IgE. 
M M is a clonal proliferation of neoplastic plasma cells which differ from 
normal plasma cells in development and function. These neoplastic cells are often 
immature and may have the appearance of plasmablasts. They produce and secrete 
excess monoclonal immunoglobulins (or paraproteins) that are mostly IgG 
paraprotein (60 %) or IgA paraprotein (20 %). Myelomas that are nonsecretory or 
secrete IgM, IgD, and IgE, are rare. 
The bone marrow microenvironment plays an important role in the pathogenesis 
of M M . Adhesion of myeloma cells to bone marrow-stromal cells triggers the 
transcription and secretion of interleukin-6 (IL-6), which is a major survival and 
growth factor for myeloma cells (Jego et al, 2001). This cytokine prevents apoptosis 
(or programmed cell death) and involves in bone lesions by activating osteoclasts 
and promoting bone resorption (Mangan, 2005). In addition, IL-6 is thought to 
mediate many of the abnormalities associated with myeloma, including anemia and 
hypoalbuminemia. 
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2.5 Clinical presentations and diagnosis 
To date, about 20 % of M M patients are without any presenting symptoms at the 
time of diagnosis. In most cases, the level of monoclonal immunoglobulins in the 
serum is used as a specific marker for the diagnosis and follow-up of M M . The 
clinical presentation of myeloma varies, but the most common features include 
anemia, bone pain, lytic lesions, recurrent infection and renal insufficiency. Other 
less common features include hypercalcemia and hyperviscosity syndrome. The 
presence of one or more of these symptoms is often the first clue in the diagnosis of 
MM. 
2.5.1 Diagnosis 
The diagnostic criteria for M M are characterized by 10 % involvement of 
plasma cells in the bone marrow or plasmacytoma in addition to one or more of other 
features, including paraproteins in serum (>3 g/dL), paraproteins in urine (>1 
g/24-hour collection) and (or) osteolytic lesions on skeletal survey. 
I f there are symptoms, suggesting that a person may have M M , laboratory 
testing of blood and (or) urine, radiographic evaluations, and a bone marrow biopsy 
wi l l be usually done. Table 2.1 shows the diagnostic evaluation for MM. 
2.5.1.1 Laboratory testing of blood and urine 
Laboratory evaluation, including complete blood count and serum chemistries, 
may reveal anemia, hypercalcemia, and an elevated level of serum total proteins. 
Serum and urine protein electrophoresis are used to detect the presence of 
monoclonal immunoglobulins. These tests should be performed when plasma cell 
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proliferation is suspected. However, in a rare form of myeloma called non-secretory 
myeloma which affects about 1 % of myeloma patients, no monoclonal 
immunoglobulins can be detected in the serum. 
2.5.1.2 Radiographic evaluations 
Approximately 80 % of patients with M M have abnormal skeletal radiographs. 
X-rays can be used to reveal bone destruction which is caused by myeloma cells. 
However, it is difficult to display small lytic bone lesions on the plain radiographs. 
Computed tomography can, therefore, reveal the small lytic lesions. Another 
alternative radiographic evaluation is magnetic resonance imaging (MRI) which can 
directly visualize a large volume of bone marrow. It is more sensitive than plain 
radiographs and computed tomography in detecting myelomatous foci. M R I studies 
showed that approximately one-third of myeloma patients who have positive M R I 
results do not exhibit lytic lesions on skeletal radiographs (Moulopoulos et al., 1993). 
Hence, MRI is used as a part of the management for M M patients. 
2.5.1.3 Bone marrow biopsy 
Plasma cell involvement can be determined from bone marrow aspirate. The 
aspirate which contains plasma cell greater than or equal to 10 % confirms a 
diagnosis of MM. 
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Table 2.1 Diagnostic evaluation for MM. (Mangan, 2005) 
Tests Findings associated with myeloma 
Complete blood count/ platelet/ T Hgb; i WBC; i platelets; T creatinine; 
differential chemistry panel T calcium; T uric acid; i albumin 
Serum protein electrophoresis + monoclonal immunoglobulin 
Quantitative immunoglobulins hypogammaglobulinemic with immune paresis 
P2-niicroglobulin elevated level-poorer prognosis 
C-reactive protein elevated level-poorer prognosis 
24-hour urine protein + monoclonal immunoglobulin / Bence Jones 
electrophoresis protein 
Bone marrow biopsy/ aspirate > 10 % involvement with plasma cells 
Skeletal survey + osteolytic lesions 
+ osteoporosis 
M R I possible cord compression, plasmacytoma and 
marrow infiltration 
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2.6 Staging and classification 
2.6.1 Staging 
There are two systems (the Durie-Salmon system and the international staging 
system) to stage MM. 
The Durie-Salmon system has been most widely accepted since 1975 (Durie and 
Salmon, 1975) (Table 2.2). It classifies myeloma into low (Stage I)，intermediate 
(Stage II) and high (Stage III) stages, according to various clinical parameters related 
to tumor mass. These parameters include the amount of monoclonal 
immunoglobulins, serum hemoglobin level, serum calcium level and the degree of 
lytic bone lesions. Moreover, each of these stages is further classified into substage A 
(serum creatinine < 2 mg/dL) and B (serum creatinine > to 2mg/dL) depending on 
the renal function. 
By contrast, the international staging system is based on the serum levels of 
p2-macroglobulin and albumin (Greipp et al, 2005) (Table 2.3). It is easier to use the 
Durie-Salmon system for staging previously untreated M M patients. 
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Table 2.2 The Durie-Salmon staging system. (Durie and Salmon, 1975) 
Stage Criteria Measured Myeloma Cell Mass 
I A l l of the following: < 0.6 cells x l O ^ W 
(Low cell mass) 
々 Hemoglobin value > 10 g/dL 
今 Serum calcium value normal or < 12 mg/dL 
今 Normal bone lesion (scale 0) 
or solitary bone plasmacytoma only 
今 Low monoclonal immunoglobulin production rate 
> IgG value < 5 g/dL; IgA value < 3 g/dL 
> Bence Jones protein < 4 g/ 24 h 
II Fitting neither stage I nor stage I I I < 0.6-1.2 cells x lO'^/M^ 
(Intermediate cell mass) 
III One or more of the following: > 1.2 cells x lO'^/M^ 
(High cell mass) 
今 Hemoglobin value < 8.5 g/dL 
今 Serum calcium value normal or > 12 mg/dL 
々 Advanced lytic bone lesions (scale 3) 
今 High monoclonal immunoglobulin production rates 
> IgG value > 7 g/dL; IgA value > 5 g/dL 
> Bence Jones > 12 g/ 24 h 
Subclassification 
A. Relatively normal renal function (serum creatinine value <2.0 mg/dL) 
B. Abnormal renal function (serum creatinine value > 2 mg/dL) 
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Table 2.3 The international staging system. (Greipp et al, 2005) 
Stage Criteria 
I Serum p 2-niicroglobulin < 3.5 mg/L 
Serum albumin > 3.5 g/dL 
II Serum p 2-microglobulin < 3.5 mg/L 
Serum albumin <3.5 g/dL 
or Serum p 2-microglobulin 3.5-5.5 mg/L 
III Serum (3 2-microglobulin > 3.5 mg/L 
2.6.2 Classification 
Myeloma can be classified into three categories so as to determine when and 
how a patient should be treated. The development of myeloma goes through the 
spectrum from benign monoclonal gammopathy through asymptomatic myeloma to 
the familiar entity of symptomatic myeloma. Their characteristics are described in 
Table 2.4. 
2.6.2.1 Monoclonal gammopathy of undetermined significance (MGUS) 
MGUS is an asymptomatic clinical state with the presence of monoclonal 
immunoglobulins in serum. No other abnormalities that are otherwise compatible 
with M M are detected at this stage. It occurs in about 1 and 3 % of individuals that 
are over 50 and 70 years old, respectively. MGUS itself is harmless; patients show 
neither hematologic nor renal dysfunction. This good health is maintained for many 
years, and the level of monoclonal proteins remains low and stable. Patients with 
MGUS need to be monitored because they can be considered to have a premalignant 
condition. Approximately 25 % of individuals progress to myeloma or a related 
malignant disease over 20 years (Kyle et al, 2002). 
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2.6.2.2 Asymptomatic MM 
Asymptomatic M M is an intermediate entity between MGUS and active MM. 
After different periods of time, asymptomatic M M often progresses to overt 
symptomatic M M which includes smouldering M M and indolent MM. 
2.6.2.3 Smouldering MM (SMM) 
Patients with SMM, like those with MGUS, remain stable for many years. 
These patients resemble M M at presentation with the absence of anemia, renal failure 
and bone disease. The levels of monoclonal immunoglobulins in SMM patients may 
slightly increase. Careful monitoring is required i f there are changes in their 
condition as indicated by skeletal radiograph or MRI scan. About half of these 
patients wi l l progress to MM, whereas the rest wi l l follow the course of MGUS. 
2.6.2.4 Indolent MM (IMM) 
I M M is very similar to SMM except the former may exhibit mild anemia and a 
few small lytic bone lesions. The disease evolves slowly but there is usually a rise in 
monoclonal immunoglobulin levels within 3 years which heralds the onset of overt 
MM. 
2.6.2.5 Symptomatic MM 
This is the most common form of plasma cell dyscrasias. It is characterized by 
numerous lytic bone lesions, overproduction of monoclonal immunoglobulins, as 
well as bone marrow infiltration with more than 30 % of plasma cells and 
plasmablasts. Patients with M M may also have anemia, kidney failure and increased 
levels of calcium in the blood. 
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Table 2.4 Classification and characteristics of MM. 
Classification Characteristics 
MGUS 
今 Serum monoclonal immunoglobulin < 3 g/dL 
今 Bone marrow plasma cells < 10 % 
今 Absence of anemia, renal failure, hypercalcemia, 
lytic bone lesions 
Asymptomatic MM 
SMM 
今 Serum monoclonal immunoglobulin > 3 g/dL 
and/or bone marrow plasma cells > 10 % 
今 Absence of anemia, renal failure, hypercalcemia, 
lytic bone lesions 
IMM 
今 Stable serum/urine monoclonal immunoglobulin 
今 Bone marrow plasmacytosis 
今 Mi ld anemia or few small lytic bone lesions 
今 Absence of symptoms 
MM 
今 Presence of serum/urine monoclonal immunoglobulin 
今 Bone marrow plasmacytosis (> 30 %) 
今 Anemia, renal failure, hypercalcemia, 




Although M M cannot be cured, it is highly treatable. The choice of therapy 
depends on the disease stage, clinical presentation, as well as the age and health of 
patient. Patients with MGUS or asymptomatic M M for many years may not need 
treatment before the disease progresses. Patients with higher M M are treated with 
induction therapy, stem cell transplantation and maintenance therapy. 
The induction therapy is designed to reduce the burden of the disease. 
Chemotherapy using alkylating agents and glucocorticoids has been widely used. 
The combination of melphalan and prednisone has also been the standard treatment 
for many years. 
The postinduction therapy by stem cell transplantation has become the standard 
regimen in most patients under age 75 years. When the patients reach the time of 
maximum response to induction therapy, transplantation of HLA-matched donor 
stems cells wi l l be performed. Approximately one-third of patients remain 
disease-free for at least four years after the transplantation. 
The maintenance therapy is long-term and low-dose treatment designed to 
prolong the duration of remission. Drugs, such as thalidomide and steroids, which 
show a moderate improvement in survival, have been used for patients with 
remission. 
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2.8 Epigenetics: DNA methylation 
Epigenetic inheritance is defined as cellular information, other than the D N A 
sequence itself that is heritable during cell division (Feinberg and Tycko, 2004). 
Cytosine D N A methylation is one of the major epigenetic changes that alter the gene 
expression without a change in nucleotide sequence. 
Cytosine D N A methylation is a covalent modification of DNA, in which a 
methyl group is transferred from S-adenosylmethionine to the carbon 5 position of 
cytosine. This reaction is catalyzed by DNA methyltransferases (DNMT) in the 
context of the 5'-CG-3' sequence, which is also referred to a CpG dinucleotide 
(Figure 2.2). D N A methylation occurs primarily at CpG dinucleotides and is 
responsible for controlling gene expression. 
The following section w i l l discuss DNA methylation as an epigenetic 
determinant of tumorigenesis. Besides, aberrant methylation o f cancer-related genes 
in M M and methodologies in searching for novel cancer-related genes wi th 
differentially methylated CpG islands (CGIs) w i l l be discussed. 
NH2 S-adonosylmethionine S-adenosylhomocysteln© NH^ 
^ DNA Methyltransferase ^ 
、NH O Z 、 N H 
Figure 2.2 Conversion of cytosine to 5'-methyl-cytosine by DNMT. 
Methylation of D N A sequences is catalyzed by DNMT, which use 
S-adenosylmethionine as donor of methyl groups. During this process, cytosine in a 
D N A molecule is methylated at the carbon 5 position of the pyrimidine ring and is 
converted to methylcytosine. (Adapted from Januchowski, 2004) 
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2.9 Fundamental aspects of DNA methylation 
2.9.1 CpG islands 
CGIs, can be found throughout the genomes, usually of length greater than 200 
bp with a GC content equal to or greater than 50 % and a CpG observed / expected 
ratio equal to or greater than 0.6 (Gardiner-Garden and Frommer, 1987). Generally, 
these regions are normally unmethylated and heavily acetylated to facilitate an open 
chromatin configuration for the interaction of transcription factors with gene 
promoters. CGIs have distinctive properties. About 70 % of CGIs are associated with 
genes and over half of them are localized to the 5' region of genes, corresponding to 
the promoter and first exon sequences. Furthermore, 56 % (or around 40,000) of 
these genes have a CGI overlapping with the transcription start site (TSS) (Larsen et 
al., 1992; Wang and Leung 2004), suggesting that CGIs are important for gene 
regulation. 
2.9.2 Roles of DNA methylation 
There is an inverse relationship between CGI DNA methylation and gene 
expression. The promoter CGI methylation is associated with gene silencing; 
whereas loss of CGI methylation results in an induction of gene transcription. 
(Tribioli et al., 1992). Numerous reports have shown the ability of promoter DNA 
methylation to inhibit transcription of a large number of genes in in vitro transfection 
assays, and in some cases, such methylation corresponds to the inactive state of the 
gene under study in vivo (Bird A 1992; Razin et al., 1991). These findings suggest 
that DNA methylation acts as a negative regulator of transcription. 
Various studies support a role for DNA methylation in the maintenance of cell-
type specific gene expression. Recent results indicate that the methylation of the 
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maspin {SERPINB5) gene promoter contributes to the cell-type specific expression 
pattern (Futscher et aL, 2002). Besides, the promoter regions of 
melanoma-associated antigen Al (MAGE-Al), belongs to a unique subset of 
germ-line specific genes, are densely methylated and unexpressed in normal somatic 
tissues, but less methylated and expressed in male germ cells (De Smet et al., 1999). 
Another role is the maintenance of X-chromosome inactivation (Jaenisch et al., 
1998). It is a dosage compensation of X-linked genes, which is achieved by 
transcriptional silencing of genes on one of the two X-chromosomes in the female, to 
ensure that female and male cells express equivalent gene expression levels (Avner et 
aL, 2001). At the onset of X-inactivation, X-chromosome inactivation center (Xist) is 
specifically transcribed in inactive X-chromosome after differentiation. This RNA 
product is spread and coats its X-chromosome to establish the inactive state. The 
promoter region of the transcriptionally active Xist allele on the inactive X 
chromosome is unmethylated, whereas that of the transcriptionally inactive Xist 
allele on the active X chromosome is highly methylated (Beard et al” 1995). 
DNA methylation is involved in parental imprinting (Wutz et al” 1997). It is a 
functional non-equivalence between maternal and paternal genomes and results in 
the gene expression from only one of the two parental alleles. The expression of 
imprinted genes is regulated by methylation. For instance, human small nuclear 
ribonucleoprotein polypeptide N {SNRPN) demonstrated the causal link between 
transcription and methylation. Both TSS and exon 1 within the CGI is extensively 
methylated on the repressed maternal allele and is unmethylated on the expressed 
paternal allele, in a wide range of fetal and adult somatic cells (Glenn et al., 1996). 
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2.9.3 Proposed mechanisms of transcriptional repression mediated by 
methylation 
Three possible mechanisms have been proposed to account for transcriptional 
repression by methylation (Figure 2.3). The first mechanism involves the direct 
interference with the binding of transcription factors to their recognition sites in the 
promoter (Rountree et al., 1997). Certain transcription factors, including AP-2, 
c-Myc/Myn, the cyclic AMP-dependent activator CREB, E2F, and NF-KB, recognize 
the promoter sequences that contain CpG residues, but their binding affinities are 
inhibited by methylation. Conversely, the binding of other transcription factors (Spl 
and CTF) are insensitive to methylation (Tate et al., 1993). Since reduction of 
binding affinity of transcription factors alone is insufficient to account for the 
inactivity o f promoters (Weih et al., 1991), this mechanism can partly explain some 
instances where DNA methylation causes gene silencing. 
The second possible mechanism for methylation-induced gene silencing 
involves two transcriptional repressors, which are methyl cytosine binding proteins 1 
and 2 (MeCP-1 and MeCP-2). These proteins bind to methylated CpG residues in 
promoter sequences and inhibit transcription initiation. MeCP-1 represses 
transcription from densely methylated promoters. Cell deficient in MeCP-1 shows 
much reduced repression of methylated genes (Boyes et al., 1992). These 
observations indicate the involvement of MeCP-1 in methylation-mediated gene 
expression. MeCP-2 is more abundant than MeCP-1 in the cells and can bind D N A 
containing a single methylated CpG dinucleotide (Meehan et al., 1992). MeCP-2 
contains a methyl-CpG binding domain that is essential for chromosomal localization. 
In addition, it contains a transcriptional repressor domain that can inhibit 
transcription from a promoter at a distance, suggesting that this protein interacts wi th 
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the transcriptional machinery or the initiation complex (Nan et al., 1997). A region 
within the transcriptional repressor domain of MeCP-2 has been shown to be 
associated with a co-repressor complex containing the transcriptional repressor 
mSinSA and histone deacetylases, suggesting a role of MeCP-2 in linking DNA 
methylation and histone deacetylation in gene regulation (Nan et aL, 1998; Jones et 
al., 1998). 
The third mechanism of transcription repression involves chromatin remodeling 
by histone lysine methylation. Histone H3 lysine 9 (H3-K9) methylation is 
associated with condensed chromatin structure and represses transcription. In 
contrast, histone H3 lysine 4 (H3-K4) methylation is associated with loosen 
chromatin structure and favors transcription. Aberrantly silenced human MutL 
homologue 1 QiMLHl) genes in tumor cells exhibit a condensed chromatin structure 
that is characterized by H3-K9 methylation and H3-K4 demethylation (Fahmer et al., 
2002). In addition, treatment of tumor cells with DNMT inhibitor 
5'-aza-2'-deoxycytidine (5-Aza-dC), reduces the level of H3-K9 methylation and 
increases the level H3-K4 methylation in the pl4 genes silenced by aberrant DNA 
methylation (Nguyen et al.’ 2002). 
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Figure 2.3 Proposed mechanisms of transcriptional repression mediated by 
DNA methylation. (Adapted from Singal et aL, 1999; Momparler, 2003) 
20 
2.10 Possible mechanisms to initiate aberrant DNA methylation 
Although the mechanisms leading to aberrant DNA methylation are unclear, 
several hypotheses have been proposed (Momparler, 2003). 
Firstly, aberrant promoter hypermethylation may be due to the infidelity of 
D N M T l . The substrate for this D N M T l is hemimethylated DNA. Methylation 
occurs immediately after DNA replication to ensure that identical methylation 
patterns are transmitted from parental cells to daughter cells. Since D N M T l is part of 
a multiprotein DNA replication complex, methylation errors may be introduced into 
the DNA during replication and accumulates aberrant DNA methylation. Aging is an 
example of the progressive increase in the number of methylated CpG dinucleotides 
(Issa et al.’ 2000). 
Secondly, other DNMT such as DNMT3a and DNMT3b (Xie et al., 1999), 
which use unmethylated DNA as template, may target the wrong CpG sequence and 
contribute to aberrant methylation. 
The third possible mechanism responsible for aberrantly methylated DNA could 
be due to a faulty repair mechanism mediated by DNMT. DNMT may function as a 
repair enzyme to correct aberrantly methylated CpG sequences (Ramchandani et al., 
1999). Repairing errors may occur and generate abnormal methylation patterns. 
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2.11 DNA methylation in tumorigenesis 
111 normal cells, the pattern of DNA methylation is conserved. When aberrant 
DNA methylation occurs, genes involved in tumorigenesis may be dysregulated, 
leading to the malignant transformation. According to the Knudsen's two-hit 
hypothesis, bi-allelic inactivation is required for complete inactivation of tumor 
suppressor genes (TSGs) (Knudson, 1971). Loss of heterozygosity (LOH), deletion, 
and mutation occur in tumor cells and contribute to the inactivation of one or both 
allele(s). However, in some instances, inactivation of the second allele may be 
mediated by DNA methylation. Numerous studies found that aberrant DNA 
methylation commonly occurs in human cancers (Figure 2.4), including (1) 
oncogenic point C — T mutation; (2) global DNA hypomethylation; and (3) regional 
DNA hypermethylation. Each of these changes, which may exist simultaneously, has 
profound influences on neoplastic progression (Baylin et al., 1998). This indicates 
that aberrant DNA methylation contributes to one of the key roles in tumorigenesis. 
2.11.1 Oncogenic point C —> T mutation 
The high mutation rate of cytosine residues within CpG dinucleotides, 
particularly those on the target site of DNMT, can account for an increased rate of 
C—T transition. Unmethylated cytosine may be converted to uracil via spontaneous, 
which is repaired by Uracil-DNA glycosylase. However, DNMT may block this 
repair, causing C—T transition at methylated CpG dinucleotides. For example, 
mutation in the p53 TSG occurs in more than 50% of human solid tumors 
(Greenblatt et al., 1994). Approximately 24 % of these mutations are C—>T transition 
at CpG dinucleotides, suggesting that DNA methylation contributes to the mutations 
(Magewu and Jones, 1994). 
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2.11.2 Global DNA hypomethylation 
Global DNA hypomethylation has been found in many types of human cancer 
including prostate metastatic tumors, D-cell chronic lymphocytic leukemia, 
hepatocellular carcinoma, cervical cancer, and high grade dysplasia of the cervix. 
Hypomethylation in cancer has been linked to chromosomal instability, particularly 
in pericentromeric satellite sequences. Several cancers such as Wilm's tumor, ovarian 
and breast cancers have been shown to frequently contain unbalanced chromosomal 
translocations with breakpoints in the pericentromeric DNA of chromosome 1 and 16 
(Qu et al, 1999). 
Promoter CGI hypomethylation can also lead to gene activation. Recently, many 
CGIs are found to be normally methylated (Strichman-Almashanu et al, 2002). 
These methylated CGIs can become hypomethylated in cancer. Examples of 
oncogenes that are affected by hypomethylation in human cancers include H-Ras 
(Feinberg and Vogelstein, 1983) and c-myc (Cheah et al” 1984). 
2.11.3 Regional DNA hypermethylation 
There are growing numbers of genes that are found to be unmethylated in 
normal tissues, but methylated in various types of human cancer. This aberrant 
methylation in tumor tissues is often associated with downregulated or even silenced 
expression of the TSGs. The first known TSG, the retinoblastoma 1 {RBI), is the first 
link between hypermethylation and TSG. Horsthemke's laboratory firstly identified 
that the RBI promoter is methylated in a significant portion of sporadic and 
hereditary retinoblastoma (Sakai et al, 1991). Methylation of RBI 5'CGI results in 
the inactivation of the gene and oncogenesis (Ohtani-Fujita et al, 1993). Another 
example is hypermethylation-induced repression of the von Hippel-Lindau (VHL) 
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gene. Loss of expression in 5 of 26 sporadic clear cell renal carcinomas occurs 
without gene mutations (Herman et al.’ 1994). The loss is due to hypermethylation of 
the VHL promoter, and treatment of a VHL non-expressing clear cell renal carcinoma 
cell line with 5-Aza-dC results in reactivation of the gene. These findings further 
support the role of hypermethylation in transcriptional repression ofTSGs. 
(1) Oncogenic point C->T mutation (2) DNA hypomethylatlon 
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Figure 2.4 Three common DNA methylation changes in tumor. (Modified from 
Singal et al” 1999) 
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2.12 Aberrant DNA methylation in MM 
Aberrant promoter methylation is an alternative mechanism to mutation or gene 
deletion for the inactivation of TSG function (Costello et al, 2000; Esteller et al, 
2001; Jones and Baylin, 2002). Cancer-related genes that are involved in the 
multi-step M M tumorigenesis can also be silenced through epigenetic alterations. 
These genes can be classified into one or more of the categories based on their 
acquired capabilities during tumor development (Hanahan and Weinberg, 2000) 
(Table 2.5). These capabilities are: (1) self-sufficiency in growth signals; (2) evading 
apoptosis; (3) insensitivity to antigrowth signals; (4) tissue invasion and metastasis; 
and (5) infinite replicative potential. Apart from these capabilities, (6) genome 
instability also facilitates tumor development. 
2.12.1 Self-sufficiency in growth signals 
Normal cells require mitogenic growth signals before they can move from a 
quiescent state into an active proliferative state. These signals are transmitted into the 
cell via transmembrane receptors that bind to signalling molecules. Generally, no 
type of normal cell can proliferate in the absence of stimulatory signals. However, 
many oncogenes in tumor cells mimic normal growth signalling by generating many 
of their own growth signals, thereby reducing their dependence on stimulation from 
their normal tissue micro environment, and enhancing their cell proliferation. 
Ras proteins are present in structurally altered forms (p21ras) that release a flux 
of mitogenic signals into cells, without ongoing stimulation by their normal upstream 
regulators (Medema and Bos, 1993). Studies have revealed that promoter 
methylation and LOH play the main mechanism for Ras association domain family 
lA gene {RASSFIA) inactivation. (Lo et al., 2001; Schagdarsurengin et al., 2002). In 
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MM, RASSFIA inactivation was detected in 60 % of cases, of which almost half of 
them (28 %) was due to DNA hypermethylation (Ng et al., 2003). 
2.12.2 Evading apoptosis 
The ability of tumor cells increase in number is determined not only by the rate 
of cell proliferation but also by the rate of cell attrition. Programmed cell death 
(apoptosis) represents a major source of this attrition. In human carcinogenesis, 
tumor cells acquire the ability to resist apoptosis. 
Bcl-2/ElB 19 kDa interacting protein (BNIP3) is a proapoptotic member of the 
Bcl-2 protein family involved in hypoxia-induced cell death (Kothari et al., 2003). 
Loss of BNIP3 expression has been shown to be associated with promoter 
hypermethylation, which occurs in 21 % of M M cases (Murai et al, 2005). Moreover, 
DAP-kinase is a proapoptotic factor induced by interferon (INFy) and loss of 
DAP-kinase expression is associated with promoter hypermethylation in 67 % of 
M M patients (Ng et al, 2001). In addition, the tumor necrosis factor through binding 
of the ligand to the antiapoptotic receptors lacking death domains {DcRl and DcR2) 
are aberrantly methylated in 55 % and 20 % of M M cases, respectively. Methylation 
of DcR2 is also detected in MGUS, suggesting that methylation of this gene is an 
early event in M M tumorigenesis (Takahashi et al, 2004). Besides, hypermethylation 
o f p 7 3 proapoptotic regulator occurs in 12.5 % of M M cases (Galm et al, 2004). 
2.12.3 Insensitivity to antigrowth signals 
Within a normal tissue, multiple antiproliferative signals operate to inhibit cell 
proliferation and maintain cellular quiescence. Cells may be forced out of the active 
proliferative cycle into the quiescent state (Go). However, tumor cells are able to 
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evade these anitproliferative signals and proceed to cell proliferation. 
Suppressor of cytokine signaling 1 (SOCSl) and Src homology 2 
domain-containing tyrosine phosphatase 1 (SHPl) negatively regulate the Janus 
kinase/signal transducer and activator of transcription (Jak/STAT) signaling pathway. 
It suppresses signaling by a wide variety of cytokines including IL-6, IL-4，leukemia 
inhibitory factor, growth hormone, prolactin, thrombopoietin and interferons 
(Greenhalgh et al., 2001). Regulation of cytokine signaling by SOCS-1 is involved in 
normal lymphocyte development and differentiation. SOCS-1 is inactivated by 
hypermethylation in about 63 % of M M patients (Galm et al., 2004). In addition, 
SOCS-1 methylation occurs in MGUS, suggesting that this epigenetic alteration is an 
early event in M M pathogenesis (Galm et al., 2004). Besides, M M and MGUS shows 
20 % SHP-1 methylation (Reddy et aL, 2005). 
2.12.4 Tissue invasion and metastasis 
The capability o f invasion and metastasis enables cancer cells to escape the 
primary tumor mass, invades adjacent tissues, and travels to distant sites where 
nutrients and space are not limiting. This migratory capability causes 90 % of human 
cancer death (Spom et al., 1996). 
E-cadherin is a cell adhesion molecule. Previous studies showed that ectopic 
repression of E-cadherin is associated with tumorigenic and invasive properties 
(Cano et al., 2000). E-cadherin is inactivated and aberrantly methylated in 21 % of 
M M cases (Galm et al, 2004). Tissue inhibitor of metalloproteinases-3 (TIMP3) is 
the inhibitor of matrix metalloproteinases, which belongs to a family o f peptidases, 
involved in degradation o f the extracellular matrix. Reduced expression o f TIMP-3 
protein is associated with increased invasiveness and reduced patient survival in 
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esophageal adenocarcinoma (Damton et al,, 2005). Interestingly, TIMP13 is 
hypermethylated in about 35 % of M M patients. Other cell adhesion molecules 
including CDHl, CDH13 and APC, have been shown to be hypermethylated in 68 %, 
37 % and less than 10 % of M M cases, respectively (Takahashi et al” 2004). 
2.12.5 Infinite replicative potential 
Hayflick revealed that cells in culture have a finite replicative potential. 
However, most types of tumor cells appear to be immortalized in culture, suggesting 
that infinite replicative potential is acquired in vivo during tumor progression and is 
essential for the development of their malignant growth state (Hayflick, 1997). 
p i5 and p i6 proteins are cell cycle regulators that inhibit of G1 phase 
progression. They complete with cyclin D for cyclin-dependent kinases 
4/cyclin-dependent kinases 6 (CDK4/CDK6) binding and inhibit CDK4/CDK6 
complex kinase activity, resulting in dephosphorylation of pRb and G1 growth arrest. 
In MM, hypermethylation of genes including the cell cycle regulators pl5 and pl6 
has been shown to correlate with gene inactivation. The frequency oipl6 and pl5 
methylation is about 36 % and 27 % in MM, respectively (Seidl et al, 2004; Ribas et 
al, 2005; Galm et al, 2004; Chen et al, 2002; Gonzalez et al” 2000), and pl6 
methylation is associated with an increased proliferative rate of plasma cells and a 
poor prognosis (Mateos et al., 2002). Methylation o f p l 6 andpl5 is also detected in 
28 % and 10 % cases with MGUS, suggesting that their methylation is an early event 
and not associated with transition from MGUS to M M (Seidl et al., 2004; Guillerm 
et al., 2001). 
Human retinoic acid-inducible E3 protein (E3)/lysosome-associated protein, 
transmembrane-5 (LAPTm5) gene {E3/LAPTm5) is a hematopoietic cell-specific 
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gene induced by retinoic acid and located at the lp34 commonly rearranged locus. 
Expression of E3/LAPTm5 is found in most hematopoietic cell lines including those 
of B-cell lineage and has been suggested to be involved in cellular differentiation. 
Methylation-induced E3/LAPTm5 gene silencing is encountered in six out of ten M M 
cell lines (Hayami et al., 2003). 
Retinoic acid receptor beta (RARP) is a nuclear transcriptional regulator. It 
binds retinoic acid and mediates cellular signaling in embryonic morphogenesis, cell 
growth and differentiation. It is thought that this protein limits growth of many cell 
types by regulating gene expression. For instance, retinoic acid receptor activates 
dopamine D2 receptor promoter in the central nervous system (Samad, 1997). 
Methylation-induced silencing of RARfi is involved in many cancers such as head 
and neck squamous cell carcinomas and esophageal squamous cell carcinoma 
(Youssef et al,’ 2004; Liu et al.’ 2004). Hypermethylation of RARJ3 is found in about 
38 % of M M patients (Takahashi et al” 2004). 
Cellular retinol-binding protein-I (CRBPl) is the carrier protein involved in the 
transport of retinol (vitamin A alcohol) from liver to peripheral tissue. Vitamin A is a 
fat-soluble vitamin necessary for the vision, growth, reproduction, and differentiation 
of epithelial tissues. Recently, it has been suggested that CRBPl downregulation 
promotes tumor progression through inhibition of retinoic acid receptor activity and 
PI3K/Akt signaling (Farias et al.’ 2005). Hypermethylation occurs in 55 % of M M 
cases (Takahashi et al” 2004). 
Retinoblastoma protein-interacting zinc finger (RIZl) encodes a zinc finger 
protein. This TSG is a member of the nuclear histone/protein methyltransferase 
superfamily. Although the functions of this protein have not been fully characterized, 
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it acts as a transcriptional activator of the heme-oxygenase-1 {HO-1) gene and may 
involve in transcriptional regulation during neuronal differentiation and pathogenesis 
of retinoblastoma. Previous studies showed that RIZl promoter methylation strongly 
correlates with decreased or loss of RIZl mRNA expression in breast, liver, colon, 
and lung cancer cell lines as well as liver cancer tissues (Du et al., 2001). 
Methylation also occurs in 15 % of M M patients (Takahashi et al, 2004). 
2.12.6 Genome instability 
A growing number of genes involved in sensing and repairing DNA damage, or 
in assuring correct chromosomal segregation during mitosis, have been found to 
inactivate in different cancers (Lengauer et al., 1998). Their loss of function causes 
genome instability, leading to the generation of tumor cells. 
06-Methylguanine DNA methyltransferase (MGMT) repairs mutagenic and 
cytotoxic 06-alkylguanine lesions produced by environmental carcinogens and 
chemotherapeutic nitrosoureas. Loss of MGMT expression has been demonstrated in 
various types of human cancer (Choy et al., 2002; K im et al., 2003; Nagel et al., 
2003; Qi et al” 2005). Interestingly, in hematopoietic malignancies, MGMT promoter 
hypermethylation is associated with a significant increase in overall survival in 
diffuse large B-cell lymphoma (Esteller et al., 2002). However, the methylation 




























































































































































































































































































































































































































































































































































































































































































































































2.13 Methodologies of DNA methylation analysis 
Many methylation strategies including DNA methylation profiling, targeted on 
the gene-specific methylation analysis such as methylation-sensitive PCR (MS-PCR), 
combined bisulfite restriction analysis (COBRA). To perform a global screening of 
aberrant methylation, methylation sensitive arbitrarily primed polymerase chain 
reaction (MS.AP-PCR) (Gonzalgo et al, 1997), restriction landmark genomic 
scanning (RLGS) (Kawai et al., 1993)，methylation sensitive representational 
difference analysis (MS-RDA) (Ushijima et al., 1997)， methylation CGI 
amplification representational difference analysis (MCA-RDA) (Toyota et al., 1999), 
differential methylation hybridization (DMH) (Huang et al., 1999) and cDNA 
microarrays combined with treatment with a demethylating agent (Suzuki et aL, 2002) 
have been developed. 
2.13.1 Genome wide screening method: MS.AP-PCR 
MS.AP-PCR is the most simple and reproducible fingerprinting technique that 
relies on cleavage of genomic DNA with the restriction enzyme Rsal to generate 
small-sized DNA fragments before digestion with either Hpall 
(methylation-sensitive) or Mspl (methylation-insensitive), both of which recognize 
the same 5’-CCGG-3' sequences. Hpall digests unmethylated sequences only, 
whereas Mspl digests both methylated and unmethylated sequences (Figure 2.5). 
Mspl serves as an internal control to determine whether the DNA fragment observed 
after Hpall digestion is due to cytosine methylation of the 5'-CCGG-3' sequence. 
Digested DNA fragments are amplified with arbitrarily GC-rich primers that 
preferentially bind to CG-rich sequences in the human genome. The resulting PCR 
products are resolved on high-resolution polyacrylamide gels. The experimental 
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results are considered valid for interpretation only when PCR product is present in 
Rsal but absent in Rsal + Mspl digestion. Four possible DNA methylation patterns 
are generated and compared in a parallel way (Figure 2.6). DNA sequences that 
display differential methylation patterns (hyper- or hypomethylation in tumor) 
between normal and tumor samples are then isolated, cloned, and sequenced. 
-..ntw.. "ait/^ T — 
Methy la ted — 4 _ 4 — ^ 
Rsa! Rsal/hpall R s a l ^ I 
PCR produc t 
Uhmethy la ted _ £ — ^ ^ 
Rsal Rsal/f-pall Rsal/^I 
PCR produc t — — 
Figure 2.5 A schematic diagram showing restriction digestion of methylated and 
unmethylated DNA sequences in MS.AP-PCR. Rsal generates small fragments of 
DNA prior to MS.AP-PCR; Hpall methylation-sensitive restriction endonuclease that 
cut unmethylated 5'-CCGG-3' sequences only; Msph methylation-insensitive 
restriction endonuclease cut both methylated and unmethylated 5'-CCGG-3' 
sequences. 
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Tumor (T) Normal (N) 
R R/H R/M R R/H R/M 
Both methylated i n N & T — 一 一 一 
Both unmethylated in N & T 一 一 
Hypermethylation in T 一 一 一 
Hypomethylation in T 一 一 一 
Figure 2.6 A schematic representation of four possible DNA methylation 
patterns by MS.AP-PCR. N represents normal samples and T represents tumor 
samples. 
2.13.2 Combined bisulfite restriction analysis 
Candidate methylation-regulated genes from the MS.AP-PCR are examined by 
a gene-specific methylation analysis called COBRA (Xiong and Laird, 1997). It is a 
powerful technique that exploits differences in restriction enzyme cutting sites 
between methylated and unmethylated DNA after sodium bisulfite modification 
(Figure 2.7). Treatment of genomic DNA with sodium bisulfite deaminates 
unmethylated cytosine residues to uracil, while methylated cytosines remain 
unchanged. After bisulfite treatment, the sequence of interest is amplified and the 
resulting PCR product wi l l represent a mixed population of methylated and 
unmethylated alleles. The PCR products are then digested with a restriction enzyme 
that has cytosine only within CpG dinucleotides in its recognition sequence. For 
example, BstUI cleaves the sequence 5’-CCGG-3’，which is retained in 
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bisulfite-treated DNA i f the cytosine is methylated, but w i l l be converted to TTGG i f 
cytosine is unmethylated. After that, the PGR digests is resolved by polyacrylamide 
gel electrophoresis. The level of methylation at specific loci can be estimated by the 
relative intensity o f the methylated or unmethylated bands. 
e s i t a a M a — — — ^ ^ ― ^ ― — s s s a s a — — — — — ; . r.fa—THHMI'UKW • iWi••； -^'vrr 
unmethylated methylated 
5， CGCG 5， CGCG 
JJ. Sodium bisulfite treated DNA 
5， UGUG 5' CGCG 
^ PGR amDiification 
5， TGTG 5， CGCG 
办 BstUI digestion 
5’ TGTG 5， C G ' ^ C G 
Unmethylated Partly Methylated Fully Methylated 
Original PGR product 
Digested PGR product 
Methylation level 0 % 50% 100% 
Figure 2.7 A schematic outline of COBRA. Modifying DNA using sodium bisulfite 
to convert unmethylated cytosines to uracils, but not 5-methylcytosines, subsequently 
detect the methylation level followed by PGR amplification and restriction 
endonuclease digestion BstUI o f CG sites. 
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2.13.3 Cloned bisulfite genomic sequencing 
The cloned bisulfite genomic sequencing (Frommer et al, 1992) is a 
gene-specific methylation analysis that bases on sequence analysis of PCR products 
generated from bisulfite-treated DNA. It provides information on the methylation 
status of every cytosine residue within the target sequence. PCR products, which are 
similar to those from COBRA, are cloned into a plasmid vector followed by 
sequence analysis of a number of individual clones. The presence of cytosine in the 
sequencing data indicates the presence of a methylated cytosine, whereas the 
presence of thymine reflects the presence of an unmethylated cytosine. 
2.13.4 Treatment with demethylating agent 
The DNMT inhibitor 5-Aza-dC is a cytosine analogue that can incorporate into 
DNA during replication. It covalently binds DNMT and inhibits its activity (Figure 
2.8). As a result, the methylation of newly synthesized DNA is inhibited and the 
number of methylated alleles are sequentially reduced after DNA replication, leading 
to global demethylation (Michalowsky and Jones, 1987). Several studies have 
demonstrated that 5-Aza-dC inhibits the growth of human tumors both in vitro and in 
vivo (Bender et al, 1998; Chao et al, 2000; Karpf al, 2001). This effect may be 
partly due to its ability to reactivate certain growth suppressors such as the pl5 
cyclin-dependent kinase inhibitor (Daskalakis et al.’ 2002). The effectiveness of 
5-Aza-dC is currently assessed for clinical trials in both solid and hematologic 
tumors (Santini et al” 2001; Aparicio and Weber, 2002; Aparicio et al” 2003), 
particularly as part of combined chemotherapy regimens for myelodysplastic 
syndrome and leukemias (Daskalakis et al., 2002). 
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Figure 2.8 Demethylation by 5-Aza-dC. (a) 5-Aza-dC binds covalently to DNMTs 
and inhibits methylation of the newly synthesized DNA strand (*); (b) 5-Aza-dC 
treatment leads to sequential reduction of methylated alleles. Black dots', methylated 
CpG dinucleotides, white dots: unmethylated CpG dinucleotides. (Adapted from 
Claus and Lubbert, 2003) 
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CHAPTER 3 MATERIALS AND METHODS 
3.1 MM specimens 
3.1.1 MM samples 
Bone marrow (BM) aspirates from 20 M M patients were obtained from the 
Prince of Wales Hospital and the Pamela Youde Nethersole Eastern Hospital from 
2000 to 2003. Samples were freshly prepared for cell sorting and frozen at -80 
Samples were classified according to the Durie-Salmon staging system (Durie and 
Salmon, 1975). Peripheral blood (PB) lymphocytes were recruited from ten unrelated 
normal donors as controls. 
3.1.2 MM cell lines 
M M cell lines (RPMI-8226, U266, OPM-2, NIC-H929 and LP l ) were obtained 
from the ATCC (American Type Culture Collection, Manassas, VA, USA). They 
were cultured in RPMI 1640 medium (Sigma-Aldrich, St Louis, MO) supplemented 
with 20 % fetal bovine serum (FBS), 1 % L-glutamine, 1 % penicillin/streptomycin 
(Invitrogen, Carlsbad, CA, USA) and incubated in 5 % CO2 at 37 
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3.2 Magnetic cell sorting of CD138-positive plasma cells 
B M samples were processed freshly for magnetic cell sorting. Mononuclear 
cells were isolated using Ficoll gradient method. Briefly, B M samples were diluted 
with one volume of degassed 1 x phosphate buffered saline (PBS) and layered gently 
onto an equal volume of Ficollpaque (Amersham Biosciences, Piscataway, NJ, USA). 
After centrifugation at 1400 rpm for 30 minutes (min) at room temperature (RT) 
without braking, mononuclear cells were collected from the interphase layer and then 
washed twice with degassed buffer A containing PBS (pH 7.2), 0.5 % BSA and 2 
m M EDTA at 1200 rpm for 10 min. 
Q 
Mononuclear cells (up to 2 x 10 ) were resuspended in the 1 ml degassed buffer 
A labeled with a CD 138 antibody (clone B-B4) conjugated with microbeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany) for 15 minutes at 4 °C. After 
incubation, cells were centrifuged at 1000 rpm for 10 min to remove non-binding 
CD 138 antibodies and the pellets were resuspended in buffer A. Magnetic cell 
sorting was performed with the MiniMACS magnetic separator (Miltenyi Biotec, 
Bergisch Gladbach, Germany). Cell suspension was applied into the MS column, 
prewashed with the degassed buffer A, which was washed twice with the degassed 
buffer A to remove any unlabeled cells (CD138-negative). The column was then 
removed from the MiniMACS magnetic separator and placed on a fresh tube. The 
degassed buffer A was added to the column and the labeled cells (CD138-positive) 
were flushed out by applying a plunger supplied with the column (Figure 3.1). The 
above magnetic separation procedure was repeated once with a new MS column to 
increase the purity of CD138-positive cells. The retained cells were centrifuged at 
6000 rpm for 3 min to remove the buffer and the pellets were stored at -80 °C. 
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Cells labeled with antibodies 
Magnetic Labeling 
Plasma cells were labeled to CD138 antibodies Q ^ 
conjugated with magnetic microbeads. ^ ^ ^ 
i 
Elution of non-labeled cell fraction 
By passing through the MACS column, the labeled 
plasma cells retained inside the column, while all the ‘ , ^ 
non-labeled cells washed out thoroughly. 
Elution of non-labeled cell fraction t 
By removing the column from the magnet, the labeled ^ 
plasma cells were collected. / 
• 暴 c \ 
Figure 3.1 Diagram showing the procedures of magnetic cell sorting of CD138-
positive plasma cells. (Modified diagram from Miltenyi Biotec.) 
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3.3 Isolation of nuclear pellet from PB 
Buffy coat was collected from the interphase layer after centrifugation at 2500 
rpm for 10 min. Red cells were lysed by mixing with 2 ml buffer CI [1.28 M sucrose, 
40 m M Tris-Cl (pH 7.5), 20 m M MgCb, 4 % Triton X-100] and 6 ml ice-cold sterile 
water. The mixture was placed at -20 for 15 min and then centrifuged at 2500 rpm 
for 15 min. The supernatant was discarded. The above red cell lysis procedures were 
repeated once. The nuclear pellet was stored at -80 
3.4 DNA extraction from MM cell lines, MM plasma cells and PB 
Cell pellets from M M cell lines, M M plasma cells or PB were digested in 3 ml 
saline Tris-ethylenediamine tetraacetic acid (Tris-EDTA) buffer containing 0.5 % 
sodium dodecyl sulfate (SDS) and 0.2 mg/ml proteinase K at 50 °C overnight. After 
digestion, an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) 
(Amersham Biosciences) was added and the mixture was vortex for 10 min before 
centrifugation at 3500 rpm for 30 min at RT. The upper aqueous layer was collected 
and DNA was precipitated by adding 1/10 volume of 3 M sodium acetate (pH 5.2) 
and 2.2 volumes of ice-cold 100 % ethanol. Following overnight incubation at -20 
the samples were centrifuged at 3500 rpm for 30 min at 4 DNA pellet was 
washed twice with 70 % ethanol. The pellet was air dried, dissolved in sterile water 
and stored at -20 The quality and quantity of DNA was determined by measuring 
absorbance at 260nm/280nm with a UV spectrophotometer. 
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3.5 Methylation sensitive arbitrarily primed polymerase chain reaction 
3.5.1 Restriction enzyme digestion of genomic DNA 
For the principles of MS.AP-PCR, please also refer to previous section 2.13.1. 
Briefly，1 |Lig DNA from each of four M M cell lines (RPMI-8226, U266, OPM-2, 
NIC-H929)，five M M plasma cell samples (CD138-positive cells) and three normal 
PB lymphocyte samples was digested separately in a total volume of 20 with 
either 15 units of Rsal, 15 units of Rsal and Hpall, or 15 units of Rsal and Mspl at 37 .. 
for 16 hours (hr), followed by an additional digestion (5 hr) with 5 units of each 
restriction enzyme to ensure complete cutting. A l l restriction enzymes were 
purchased from New England Biolabs (NEB, Beverly, MA, USA). 
3.5.2 Arbitrarily primed polymerase chain reaction 
The AP-PCR was performed according to the Markl et al (Markl et aL, 2001). 
Digested fragments (50 ng) were amplified with a combination of two or three 
arbitrary GC-rich primers (Tables 3.1 and 3.2). Conditions for amplification were: hot 
start at 95 °C for 6 min, followed by 42 cycles of 94 °C for 2 min, 40 °C for 1 min, 
and 72 °C for 2 min, and a final extension at 72 °C for 10 min. The PCR mix 
contained GeneAmp 1 x Buffer I I (Applied Biosystems), 1.5 mM MgCl2, 200 | iM 
each of the four deoxynucleotide triphosphates (dNTP), 10 pmol each of primers, 0.5 
unit of AnipliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA, 
USA), and 4 |iCi of a^^P-labeled dATP (Perkin Elmer, Foster City, CA, USA) in a 
final volume of 10 |j.1. 
The PCR product was diluted with formamide dye buffer [95 % formamide, 20 
m M EDTA (pH8.0), 10 mM NaOH, 0.05 % bromphenol blue and 0.05 % xylene 
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cyanol], denatured at 95 °C for 3 min, and then immediately cooled on ice. Samples 
(2.5 |j,l) were resolved on 5% denaturing polyacrylamide gels (7M urea) for 90 min at 
a constant voltage o f 1700 V’ 300 mA, and 110 W. After electrophoresis, the gel was 
dried at 80 °C for 3 hr and exposed to an autoradiographic f i lm with an intensifying 
screen at -80 °C overnight. 
3.5.3 Isolation of differentially methylated DNA fragments 
Differentially methylated DNA fragments were identified visually by comparing 
the pattern among the three sets of restriction enzymes digestions. Candidate bands 
were excised from the gel and placed in a microcentrifuge tube containing 40 \i\ 
sterile water. The tube was incubated at 60 °C for 1 hr and vortex occasionally to 
facilitate the dissolution of the DNA fragments. The eluted D N A (1.5 |il) was 
re-amplified with the same primers as those used for AP-PCR to generate sufficient 
template for cloning and sequencing. Conditions for re-amplification were: initial 
denaturation at 95 °C for 2 min, followed by 45 cycles of 94 °C for 60 sec, 49 °C for 
45 sec, and 72 °C for 45 sec, and a final extension at 72 °C for 10 min. The PGR mix 
contained 1 x buffer [10 m M Tris-HCl (pH 9.0), 1.5 m M MgCb and 50 m M KCl] , 
200 | i M eachof dNTP, 12.5 pmol each of primers, 5 % dimethyl sulfoxide (DMSO) 
and 1 unit o f r ^ ^ D N A polymerase (Amersham Biosciences) in a final volume of 25 
|il. PGR products were resolved on 2 % (w/v) agarose gels with 0.5 |ig/ml ethidium 
bromide in 1 x TBE buffer (89 m M Tris-base，98 m M boric acid, 2 m M EDTA). 
Targeted fragments were extracted using the Gel Extraction Ki t (Qiagen, Valencia, 
CA, USA) and eluted with 30 |i l in sterile water. 
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Table 3.1 Primer sequences for MS.AP-PCR. 
Primer Primer sequences 
G1 5'-GCG CCG ACG T-3' 
G2 5'-CGG GAC GCG A-3' 
G3 5'-CCG CGATCG C-3' 
G4 5’-TGG CCG CCG A-3' 
G5 5,-TGC GAC GCC G-3' 
GCl 5,-GGG CCG CGG C-3' 
GC2 5,-CCC CGC GGG G-3' 
GC4 5'-GCG CGC CGC G-3’ 
GC5 5'-GCG GGG CGG C-3' 
T I M l 5’-AGC GGC CGC G-3’ 
TIM7 5'-GAG GTG CGC G-3' “ 
TIMIO 5’-AGG GGA CGC G-3’ 
T I M l 1 5'-GAG AGG CGC G-3' 
TIM12 5'-GCC CCC GCG A-3' 
TIM13 5,-CGG GGC GCG A-3' 
T I M 17 5'-GGG GAC GCG A-3, 
TIM18 5'-ACC CCA CCC G-3' 
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Table 3.2 Primer sets for MS.AP-PCR. 
Primer set number Primer combinations 
1 G2, G4, G5 
2 GC1，GC4 
3 GC1,GC5 
4 GC2, GC5 
5 TM1，TIM7 
6 TIM1,TIM18 






13 G4, GC4, T M I O 
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3.6 Cloning of differentially methylated DNA fragments 
3.6.1 TA cloning 
Cloning of PCR products was performed using the TA Cloning Ki t (Invitrogen). 
Eluted PCR fragments were ligated into the linearized pCR2.1 vector (12.5 ng) in the 
presence of 1 x ligation buffer and 1 Weiss units T4 DNA ligase. The final reaction 
volume was 5 |il. The ligation mixture was incubated at 14 °C overnight. 
3.6.2 Heat shock transformation 
Transformation was performed according to the recommendation of TA Cloning 
Kit. Twenty-five microliters cells (Top 10) were thawed on ice. Two microliters of 
the ligation reaction was added into the cells and the mixture was stirred with the 
pipette tip. After incubation on ice for 30 min, the cells were heat shock for 30 sec at 
42 without shaking and then immediately kept on ice. S.O.C. medium (250 |il) 
was added to the cells, and the vial was shaken horizontally (225 rpm) at 37 for 1 
hour in a shaking incubator. Following incubation, cells (120 |il) from each 
transformation was spread on LB agar plates [1 % tryptone, 0.5 % yeast extract, 1% 
NaCl, 15% agar (pH7.0)] containing 0.1 mg/ml ampicillin, 0.8 mg X-gal and 
incubated overnight at 37 to allow for blue/white selection. 
3.6.3 Screening of positive clones by PCR 
For the analysis of positive clones, at least five white colonies were picked and 
analyzed by PCR to ensure the proper size of insert. Conditions for amplification 
were: hot start at 95 °C for 10 min, followed by 35 cycles of 94 °C for 30 sec, 55 °C 
for 30 sec, and 72 °C for 40 sec, and a final extension at 72 °C for 5 min. Each 20 |xl 
PCR reaction contained GeneAmp 1 x Buffer II, 1.5 m M MgCb, 200 |xM each of 
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dNTP, 8 pmol each of primers (Table 3.3: T7 promoter and M13 reverse), and 0.5 
unit of AmpliTaq Gold DNA polymerase. PGR products were resolved on 2 % (w/v) 
agarose gels. 
3.6.4 Alkaline lysis for plasmid DNA preparation 
Bacterial colonies positive for insert DNA were cultured in 2 ml LB broth 
(Amersham Biosciences) containing 0.1 mg/ml ampicillin at 37 overnight with 
shaking at 225 rpm. Cells were centrifuged at maximum speed for 20 sec to remove 
the LB medium. The pellet was resuspended in 100 j i l GTE buffer [50 m M glucose, 
25 m M Tris-Cl (pH 8.0), 10 m M EDTA] and left at RT for 5 min to lyse the bacterial 
membrane. Bacterial protein, chromosomal and plasmid DNA was denatured with 
200 |j,l containing 0.2 M NaOH / 1 % SDS. The tube was inverted upside down for 
ten times and then placed at RT for 5 min. The mixture was neutralized with 150 j i l 
o f 5 M potassium acetate (pH 4.8) and inverted upside down for ten times, followed 
by incubation on ice for another 5 min. Debris was cleared by centrifugation at 
maximum speed for 5 min at 4 and the supernatant was transferred to a fresh tube. 
DNA was precipitated by ethanol precipitation and the pellet was washed twice with 
70 % ethanol. The pellet was air dried and resuspended in 50 |il. 
3.7 MS.AP-PCR sequence analysis 
3.7.1 Nucleotide sequencing 
Nucleotide sequencing was performed according to the instructions of the 
BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems). Plasmid DNA 
(0.5-1.0 |ig) was sequenced with the M13 reverse primer. (Table 3.3). Conditions for 
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sequencing reaction were: initial denaturation at 96 °C for 1 min, followed by 30 
cycles of 96 °C for 10 sec, 50 °C for 5 sec, and 60 °C for 4 min. The reaction mix (10 
|0.1) contained 1 x BigDye sequencing buffer, 1 x ready reaction premix and 10 pmol 
each of primer. Sequencing products were purified by sephadex G-50 spin columns 
(Amersham Biosciences). The eluted sample was mixed with an equal volume of the 
template suppression reagent (Applied Biosystems) and then denatured at 95 °C for 3 
min. Electrophoresis was performed using an ABI prism 3100 genetic analyzer 
(Applied Biosystems). Sequence homologies were determined using the BLAST 
programme of the National Center for Biotechnology Information (NCBI) 
(http://www.ncbi.nih.gov/BLAST). 
3.7.2 CGIs analysis of differentially methylated sequences 
MS.AP-PCR fragments were verified by the presence of Hpall restriction site(s) 
in their sequence. Genomic regions surrounding the corresponding Hpall site(s) were 
analyzed by the UCSC Genome Bioinformatics (http://www.genome.ucsc.edu/) to 
search for putative CGIs, which are defined as DNA regions greater than 200 bp, 
with a GC content above 0.5 and an observed/expected CpG ratio above 0.6 
(Gardiner-Garden and Frommer, 1987). 
3.8 DNA methylation analysis 
3.8.1 Sodium bisulfite modification 
Sodium bisulfite modification of genomic DNA was performed using the EZ 
DNA Methylation Ki t (Zymo Research, Hornby, Canada) according to the 
manufacturer's instruction. Briefly, genomic DNA (0.5 ng - 2 )ig) was mixed with 5 
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I l l o f M-Di lu t ion Buffer, and adjusted to 50 sterile water, and then incubated at 37 
°C for 15 min. CT Conversion Reagent (100 [i\) was added and the sample was 
incubated in the dark at 50 °C for 16 lir. After incubation on ice for 10 min, 400 |i l of 
M-Binding Buffer was added and the mixture was loaded into a Zymo-Spin I 
Column. The column was then washed sequentially with M-Wash Buffer (200 pi), 
M-Desulphonation Buffer (200 |il), and Wash Buffer (200 |il) before eluted with 40 
|xl sterile water. 
3.8.2 Combined bisulfite restriction analysis 
As mentioned previously (section 2.13.2)，COBRA was performed to determine 
the methylation level of specific gene locus. Bisulfite-modified D N A was amplified 
wi th primers designed by the MethPrimer Program 
(http://www.urogene.org/methprimer/). PGR was performed in 20 |i l reaction 
containing GeneAmp 1 x buffer II，2 m M MgCh, 200 \ iM each of dNTP, 10 pmol 
each o f primers, 0.5 unit of AmpliTaq Gold DNA polymerase and 75 ng DNA. 
Primer sequences and PGR conditions were shown in Table 3.3. PCR products were 
digested wi th BstUI at 60 °C overnight. PCR digests were then resolved on 
nondenaturing 10 % polyacrylamide gels, stained with 0.5 j ig/ml ethidium bromide 
in 1 X TBE buffer and visualized under UV illumination. 
3.8.3 Cloned bisulfite genomic sequencing 
The remaining PCR products from COBRA were TA-cloned into the pCR2.1 
vector (Invitrogen) and plasmid DNA was prepared and sequenced using the A B I 
prism 3100 genetic analyzer as described previously to identify the methylation 
status o f each CG site among the specific locus. 
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3.9 Gene expression analysis 
3.9.1 RNA extraction 
Total RNA was extracted by TRIzol Reagent (Invitrogen) according to the 
manufacturer's instructions. Briefly, cells (up to 1 x lO?) were homogenized 
completely in 1 ml TRIzol Reagent and then incubated at RT for 5-10 min. 
Chloroform (200 |ji) was added to each sample. The mixture was shaken for 15 sec 
and incubated at RT for another 5 min. Samples were centrifuged at 14000 rpm for ,, 
15 min at 4 and separated into two layers. The upper aqueous phase was 
transferred to a fresh tube, mixed with 0.5 ml isopropyl alcohol and incubated at -20 
°C for 30 min before centrifugation at 14000 rpm for 20 min to precipitate the RNA. 
The pellet was washed twice with 75 % ethanol, air dried and dissolved in 40 pi 
RNase-free water. Contaminating DNA was eliminated from the samples by 
RNase-free DNasel digestion (Amersham Biosciences). Total RNA was extracted 
again to remove the DNasel. The quality and quantity of total RNA was determined 
by measuring absorbance at 260nm/280nm with a UV spectrophotometer. 
n 
3.9.2 Reverse transcription PCR (RT-PCR) 
First-strand cDNA was synthesized from 1 |ig of total RNA using MuLV reverse 
transcriptase (Applied Biosystems). Conditions were: 22 °C for 25 min, 42 °C for 65 
min, and 92 °C for 2 min. The 20 |i l reaction contained reverse transcriptase (50 
units), random hexamer (50 pmol), RNase inhibitor (20 units), Gene Amp 1 x Buffer 
II，5 m M MgCl2 and 10 m M dNTR Primers were designed by the Primer 3 program 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Primer sequences and 
PCR conditions are shown in table 3.3. The expression of target cDNA was 
normalized to that of the GAPDH cDNA, which served as an internal control. 
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3.9.3 5'-aza-2'-deoxycytidine treatment 
Cells were seeded at a density of 1 x 10^ cells/ml in 25 cm^ culture flasks and 
allowed to grow for 24 hr. Afterwards, cells were treated with various concentrations 
of 5 '-aza-2'-deoxycytidine (Sigma-Aldrich) for four days. Drugs were replenished 
every 48 hr. Controlled cells were treated with an equivalent concentration of vehicle 
(DMSO). 
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Table 3.3 Primer sequences and PCR conditions for nucleotide sequencing, 
COBRA and semi-quantitative RT-PCR. 
Gene Primer sequences Tm (°C) '^le^J^^^p)^ Purpose 
T7 promoter Forward: 5'-TAA TAC GAC TCA CTA TAG-3’ … • … o 
Ml3 Reverse: 5,-AGG AAA CAG CTA TGA CCA-3’ Not available Sequencing 
Bi-forward: 5'-AGA TTT TTA ATT AGT TTT AGA TTT GG-3' 
Bi-reverse: 5'-ACT CAA CAA ACT ATT AAT CTT AAC CAC-3' 仍 LOBRA 
Bi-forward: 5'-ATG ATA AGG GAG AAA AAT TTT TTT A-3' „ . 
證 ^ Bi-reverse: 5'-CCA ACA ACC AAA CTC TAA AAA CTC-3' 、丨 • ^ � LUBKA 
RT-forward: 5'-AGC AAG GAA AGC AAC AAA AC-3' 
RT-reverse: 5'-AGT GCT GGA AAA GGA AGT TG-3, 
n ^ p j o n RT-forward: 5’-CCT CAG ACC AGG AAG AGC AC-3' 
KNtJOU „ „ C’ AT^ P /^ A A r^ A/"! "71 191 RT-PCR RT-reverse: 5’-ATG ATC CAG CAA TCC CAC TC-3 
Pf^H R丁-forward: 5,-TCT AGA CGG CAG GTC AGG TCC ACC-3' 
RT-reverse: 5'-CCA CCC ATG GCA AAT TCC ATG GCA-3' k 卜 n^K 
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CHAPTER 4 RESULTS 
4.1 Generation of DNA methylation patterns by MS.AP-PCR 
A representative MS.AP-PCR gel image showing the methylation patterns in 
M M cell lines, primary M M tumors and normal PB lymphocytes was shown in 
Figure 4.1. The experimental results were only considered valid for further 
evaluation when bands were present in Rsal but absent in Rsal + Mspl digestions. 
This band pattern was regarded as evaluable for further interpretation of the 
methylation status with respect to corresponding DNA sequence. Presence or absence 
of PCR product with Rsal + Hpall digestion indicated positive methylation or 
unmethylation of the corresponding DNA sequences, respectively [Figure 4.1(A)]. 
Status of methylation could be established across all M M cell lines, primary M M 
tumors and normal PB lymphocytes in a total of 78 DNA sequences for comparative 
analysis. The difference in methylation status between M M samples (cell lines or 
primary tumors) and normal PB lymphocytes was considered as differential 
methylation [Figure 4.1(B)]. Hypermethylation in tumor was indicated by the 
positive methylation status in one or more tumor samples, but unmethylation status 
in all normal PB lymphocyte samples. Hypomethylation in tumor was indicated by 
the positive methylation status in all normal PB lymphocyte samples but 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.1.1. Global methylation content in MM samples and normal PB lymphocytes 
The methylation pattern of the 78 DNA sequences in the four M M cell lines, 
five primary M M tumors and three normal PB lymphocyte samples was summarized 
in Table 4.1. The number of methylated DNA sequences identified in the normal 
group was 41 (53 %)，40 (51 %) and 38 (49 %) in RB. l , P.B.2 and P.B.3, respectively; 
in M M cell lines was 31 (40 %)，29 (37 %), 42 (54 %) and 40 (51 %) in RPMI-8226, 
U266, 0PM2 and NCI-H929, respectively; in primary M M tumors was 31 (40 %), 
36 (46 %), 40 (51 %), 29 (37 %) and 42 (54 %) in M M l , MM2, MM3, MM4 and 
MM5, respectively. 
The consistency of the methylation status of the 78 DNA sequences varied 
among groups. Nearly all (74/78; 95 %) DNA sequences showed a consistent 
methylation status among normal PB lymphocytes. In contrast, the number of 
consistently methylated DNA sequences in M M cell lines and primary M M tumors 
was only 39 (50 %) and 23 (29 %), respectively. 
4.1.2. Differential methylation in MM 
The number of hypermethylated DNA sequences identified in RPMI-8226, 
U266, OPM-2 and NCI-H929 cell lines was 9 (12 %), 10 (23 %), 17 (22 %) and 11 
(14 %), respectively, whereas that identified in M M l , MM2, MM3, MM4 and MM5 
primary tumors was 2 (3 %)，5 (6 %)’ 9 (12 %)，3 (4 %) and 7 (9 %), respectively. As 
a whole, there were 24 DNA sequences showing hypermethylation in the M M tumors 
when compared with the normal group (Table 4.1). 
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On the other hand, the number of hypomethylated DNA sequences identified in 
RPMI-8226, U266, OPM-2 and NCI-H929 cell lines was 17 (22 %)，20 (26 %)，12 
(15 %) and 9 (12 %)，respectively, whereas that identified in M M l , MM2, MM3, 
MM4 and MM5 primary tumors was 11 (14 %)，8 (10 %)，10 (13%), 13 (17 %) and 5 
(6 %) respectively. Overall, there were 24 DNA sequences exhibiting 
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The methylation status ( # , methylated;〇，unmethylated) of the 78 evaluable DNA 
sequences in four M M cell lines (RPMI-8226, U266, OPM-2 and NCI-H929), five 
primary M M samples (labelled MM1-MM5), and three normal PB lymphocytes 
(labelled PB1-PB3) was shown. Their methylation status was classified as, (1) 
hyermethylation in tumor: the positive methylation status in one or more tumor 
samples, but unmethylation status in all normal PB lymphocyte samples (2) 
hypomethylation in tumor: the positive methylation status in all normal PB 
lymphocyte samples but unmethylation status in one or more tumor samples (3) No 
methylation change: DNA sequences of the entire samples were either methylated or 
unmethylated, (4) Not gradable: Normal PB lymphocyte samples showed 
inconsistent methylation pattern. (M) The methylation levels (%) in each sample 






4.2 UCSC BLAT analysis of differentially methylated DNA sequences 
UCSC BLAT analysis of the 48 differentially methylated DNA sequences (24 
hypermethylated and 24 hypomethylated) indicated that 24 of them were adjacent to 
or contained defined CGIs (fragment length > 200 bp, GC content > 50 %, CpG 
observed / expected ratio > 0.6) (Gardiner-Garden and Frommer, 1987). 
Among these 24 candidates, 8 showed no homology to any mRNAs or 
expressed sequence tags (ESTs) while the rest mapped to the 5' flanking (n=12) or 
other (n=4) regions of known or novel genes (Table 4.2). 
4.3 Identification of two candidate genes with downregulated expression 
The mRNA level of the 16 known or novel genes (listed in Table 4.2) in five 
M M cell lines (RPMI-8226, U266, OPM-2, NCI-H929 and LP l ) was examined by 
semi-quantitative RT-PCR to identify candidates that may be regulated by CGI 
methylation. Two of them [zinc fingers and homeoboxes {ZHX2) and ring finger 
protein 180 {RNFISO)] were found to be downregulated in certain M M cell lines 
(wi l l be discussed in details in later sections), while the others {FAT, PAX6, NCDN, 
TP53TG3, ETVl, TMEFF2, GTF2F1’ KBTBD6, FUT8, GPR149, ALX4, TBX5’ 
hypothetical protein FLJ27219 and cDNA clone CS0DI084YD16) showed no 
significant change in expression among the samples. Hence, ZHX2 and RNFISO were 


















































































































































































































































































































































































































































































































































































































































































































































4.4 Zinc fingers and homeoboxes 2 (ZHX2) 
4.4.1 ZHX2 CGIs BLAT search analysis 
BLAT analysis (UCSC genome browser gateway) indicated that the ZHX2 gene 
resided in a CGI that extended from the promoter region to part of the intron 1 of the 
gene (Figure 4.2). This CGI was 2573 bp and has a GC content of 57 % and an 
observed / expected CpG ratio of 0.95. 
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Figure 4.2 UCSC BLAT analysis of ZHX2. As shown in the graph, GC percent 
indicates the content of CG dinucleotides. Black rectangle indicates the location of 
the differentially methylated sequence. Blue rectangle indicates the location of the 
ZHX2 gene, and green rectangle indicates the CGI. 
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4.4.2 Hypermethylation oiZHX2 in MM cell lines 
COBRA was performed to evaluate the methylation status of ZHX2 promoter in 
five M M cell lines and two samples of normal PB lymphocytes. The PCR product 
was designed to span from nucleotide -840 to -468 of the ZHX2 promoter region 
[nucleotide position was relative to the TSS which was assigned as +1]. This region 
contained 27 CpG dinucleotides and three BstUI restriction sites [Figure 4.3(A)]. As 
shown in Figure 4.3(B), partial methylation of the ZHX2 promoter region occurred in 
two out of five M M cell lines (U266 and OPM-2). Two methylated bands were 
detected in U266, while only one methylated band was detected in OPM-2. This 
indicated that ZHX2 promoter methylation occurred at different BstUI sites in the two 
cell lines. In contrast, the ZHX2 promoter was unmethylated in the other three M M 
cell lines (NCI-H929, RPMI-8226 and LP-1) and the two normal PB lymphocyte 
samples. 
To determine the methylation density of the ZHX2 promoter region, cloned 
bisulfite sequencing was carried out for two representative methylated cell lines 
(U266 and OPM-2) and one normal PB lymphocyte sample. Figure 4.3(C) showed 
that all the PCR clones analyzed were partially methylated in U266 and OPM-2 cell 
lines, which had an overall methylation level of 30 % and 24 %, respectively. 
Conversely, all the CpG sites in the ZHX2 promoter were unmethylated in the normal 
PB lymphocyte sample. These bisulfite sequencing data were in accordance with 
those obtained by COBRA. 
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Figure 4.3 (A) A schematic diagram showing the position of BstUI cut sites in the 
ZHX2 promoter region. The location of CpG dinucleotides {vertical red lines) is 
indicated within the CGI. The TSS is marked with a bent arrow and assigned as +1. 
The hatched box represents the 5' untranslated region, and exon 1 is located +291 
downstream of the TSS. The region of COBRA and bisulfite sequencing analysis 
spans from -840 to -468. Cleavage of the PCR product (373 bp) with BstUI yielded 
various bands (226 bp, 6Ibp and 58bp); (B) COBRA analysis of the ZHX2 
promoter region. Gel picture showing the methylation status of the ZHX2 promoter 
region in five M M cell lines and two samples of normal PB lymphocytes. 
Unmethylated and methylated bands were indicated by arrows. The methylation 
status of each sample was indicated at the bottom of the figure. M: methylation; U: 
unmethylation. PCR mixture with H2O served as a negative control; (C) Cloned 
bisulfite sequencing analysis of the ZHX2 promoter. Five PCR clones from each 
sample (U266, OPM-2 and normal PB lymphocytes) were sequenced. Each row of 
squares represents one PCR clone, and each square represents a CpG site, {red 
square: methylated; white square: unmethylated). The overall methylation level of 
the ZHX2 promoter in each sample was shown in the right column. 
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4.4.3 Downregulated expression of ZHX2 in methylated MM cell lines 
Semi-quantitative RT-PCR analysis of ZHX2 expression in five M M cell lines 
was shown in Figure 4.4. Reduced and loss of expression of ZHX2 mRNA was 
detected in OPM-2 and U266 cell lines, respectively, which exhibited partial ZHX2 
promoter methylation. In contrast, all unmethylated M M cell lines (NCI-H929, 
RPMI-8226 and LP-1) expressed ZHX2 transcripts. These results suggested that 
ZHX2 promoter hypermethylation suppresses its expression in M M cell lines. 
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Figure 4.4 Semi-quantitative RT-PCR analysis of ZHX2 expression in MM 
cell lines. Gel image showing the expression of ZHX2 mRNA in five M M cell lines. 
ZHX2 mRNA expression was silenced in U266 and downregulated in OPM-2. PCR 
mixture with H2O served as a negative control. Amplification of GAPDH cDNA was 
performed as an internal control for RNA integrity. 
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4.4.4 Restoration of ZHX2 expression by 5-Aza-dC treatment 
To confirm a role of ZHX2 promoter hypermethylation in controlling ZHX2 
expression, ZHX2 non-expressing U266 cell line was treated with various 
concentrations of 5-Aza-dC for 96 hours. Figure 4.5 showed that the demethylation 
agent induced a dose-dependent increase in ZHX2 mRNA levels in U266 cells. 
Conversely, no significant change in GAPDH expression was observed. These data 
further indicated that methylation of the ZHX2 promoter inhibits its expression in 
M M cell line. 
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Figure 4.5 Reactivation of ZHX2 expression by S-Aza-dC. The non-expressing 
U266 cell line was treated with various concentrations (1, 3, 5 and 10 uM) of 
5-Aza-dC for 96 hours. Total RNA was extracted from untreated and treated cells for 
RT-PCR analysis. ZHX2 mRNA expression was dose-dependently restored after 
5-Aza-dC treatment. PCR mixture with H2O served as a negative control. 
Amplification of GAPDH cDNA was carried out as an internal control for RNA 
integrity. 
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4.4.5 Unmethylation of ZHX2 in primary M M tumors 
We next examined whether hypermethylation of the ZHX2 promoter could be 
detected in primary M M tumors. We used COBRA to evaluate ZHX2 promoter 
hypermethylation in 24 primary M M tumors (CD138-positive cells) and five samples 
o f normal PB lymphocytes. As shown in Figure 4.6, the ZHX2 promoter was found to 
be unmethylated in all the 24 primary M M samples and the five normal PB 
lymphocyte samples. To further evaluate the methylation status of each CpG site, 
cloned bisulfite sequencing was performed for three primary M M samples. Our 
results showed that all the CpG sites were unmethylated in these primary samples 
(data not shown). 
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Figure 4.6 A representative gel image of COBRA analysis of the ZHX2 
promoter in eight M M tumors and two normal PB lymphocyte samples. 
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4.5 Ring finger protein 180 (RNF180) 
4.5.1 RNF180 CGIs BLAT search analysis 
BLAT analysis (UCSC genome browser gateway) indicated that the RNF180 
gene resided in a CGI that extended from the promoter region to part of the intron 1 
of the gene (Figure 4.7). This CGI was 658 bp and has a GC content of 72 % and an 
observed / expected CpG ratio of 1.0. 
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Figure 4.7 UCSC BLAT analysis of RNF180, As shown in the graph, GC 
percent indicates the content of CG dinucleotides. Black rectangle indicates the 
location of the differentially methylated sequence. Blue rectangle indicates the 
location of the ZHX2 gene, and green rectangle indicates the CGI. 
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4.5.2 Hypermethylation of RNFl80 in MM cell lines 
We also applied the same approach to study the methylation status of the 
RNFl 80 promoter in five M M cell lines and two normal PB lymphocyte samples 
using COBRA. The PGR product was designed to span from nucleotide -247 to +54 
relative to the TSS. This region contained 43 CpG dinucleotides and six BstUI 
restriction sites [Figure 4.8(A)]. As shown in Figure 4.8(B), methylation of the 
RNFl 80 promoter region occurred in three out of five M M cell lines (U266, 
NCI-H929 and OPM-2) as indicated by the presence of multiple bands following 
BstUI digestion. In contrast, the RNFl80 promoter was unmethylated in the other 
two M M cell lines (RPMI-8226 and LP-1) and the two normal PB lymphocyte 
samples. 
To determine the methylation density of the RNFl 80 promoter region, cloned 
bisulfite sequencing was carried out for five M M cell lines and one normal PB 
lymphocyte sample. Figure 4.8(C) showed that all the PCR clones analyzed were 
densely methylated with an overall methylation level of 70 %, 65 % and 90 % in 
U266, NCI-H929 and OPM-2, respectively. The RNFl 80 promoter was barely 
methylated (3 %) in LP l . In contrast, all the CpG sites were unmethylated in 
RPMI-8226 and normal PB lymphocytes. These bisulfite sequencing data were in 
accordance with those obtained by COBRA. 
70 
(A) 
RNF180 CpG island r ^ 
“ ‘“ “ " " “ III ‘ " " I ' “ “ III I Nil mil ‘ I E父门 n ^ ^ / / 
+1 
- ^ f V n JlJl II H ^ " ^ ^ J ^ O b p 
CpG sites丨丨丨丨卜丨丨丨丨丨”丨I I I IH I I I Pui I I , uCf \丨丨p丨卞丨丨叫丨丨 
l l^t l^f一27bp_ 2bp 8Sbp • I • 38bp 丨 38bp 
I- BsiUf cutting site 
(B) 
M M cel l l ines N o r m a l PB 
IVIurkcr I R|>]Vfi “ I 
P B l PB2 H20 1 




M M U M U U U M e t h y l a t i o n s t a t u s 
(C) 
CPG sites M ' • Degreeof 
f U266 M 
I — u . 
i i f " ^ ^ ^ ^ M M J I M M M 30. 
園 B B H H ^ H H I M -
Normal PB = : = 二 二 二 - - | | | | | | | | | | | | | | | | | | | | | | | U I | | | | | [ T T 
lymphocytes =================== ,, j I丨丨丨丨丨丨丨丨丨丨丨丨丨丨I j~H+二：：：：=::=：；-=二二 “ 0% 
• Methylated CpG site 
F i g u r e 4 . 8 口 Unmethylated CpG site 
71 
Figure 4.8 (A) A schematic diagram showing the position of BstUI cut sites in the 
RNF promoter region. The location of CpG dinucleotides {vertical red lines) is 
indicated within the CGI. The TSS is marked with a bent arrow and assigned as +1. 
The hatched box represents the 5' untranslated region, and exon 1 is located +110 
downstream of the TSS. The region of COBRA and bisulfite sequencing analysis 
spans from -247 to +54. Cleavage of the PCR product (301 bp) with BstUI digestion 
is shown in the figure; (B) COBRA analysis of the RNF 180 promoter region. Gel 
picture showing the methylation status of the RNF 180 promoter region in five M M 
cell lines and two samples of normal PB lymphocytes, Unmethylated and methylated 
bands were indicated by arrows. The methylation status of each sample was 
indicated at the bottom of the figure. M: methylation; U\ unmethylation. PCR 
mixture with H2O served as a negative control; (C) Cloned bisulfite sequencing 丨 
I 
analysis of the RNF 180 promoter. Five cloned PCR products from five M M cell I 
lines (U266, NCI-H929, RPMI-8226, OPM-2, LP-1), two primary M M tumors j 
(MM3 and MM4) and one normal PB lymphocyte sample were sequenced. Each row I' 
of squares represents one PCR clone, and each square represents a CpG site, {red 
square: methylated; white square: unmethylated). The overall methylation level of 
the RNF 180 promoter in each sample was shown in the right column. 
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4.5.3 Downregulated expression of RNFISO in methylated M M cell lines 
Semi-quantitative RT-PCR analysis of RNFISO expression in five M M cell lines 
was showed in Figure 4.9. Loss of expression of RNFISO mRNA was detected in 
U266, NCI-H929 and OPM-2 cell lines, respectively, which exhibited RNFISO 
promoter methylation. In contrast, the unmethylated M M cell lines (RPMI-8226 and 
LP-1) expressed RNFISO transcripts. These results suggested that RNFISO promoter 
hypermethylation suppresses its expression in M M cell lines. 
！ t 
i: 
MM cell lines 
( Y 縱 • 溫 B ()PM-2 L P “ H 2 0 
I P i i ^ l l — — m — 
^ m ^ ^ ^ ^ ^ Q ^ ^ ^ ^ ^ ^ * . � 丨 没 , / W F i 洲（191 bp) 
Figure 4.9 Semi-quantitative RT-PCR analysis of RNFISO expression in M M 
cell lines. Gel image showing the expression of RNFISO mRNA in five M M cell 
lines. RNFISO mRNA expression was silenced in U266, NCI-H929 and OPM-2. 
PCR mixture with H2O served as a negative control. Amplification of GAPDH cDNA 
was performed as an internal control for RNA integrity. 
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4.5.4 Restoration ofRNFlSO expression by 5-Aza-dC treatment 
To confirm a role of RNF180 promoter hypermethylation in controlling its 
expression, RNF180 non-expressing M M cell lines (U266, NCI-H929 and OPM-2) 
were treated with various concentrations of 5-Aza-dC for 96 hours. Figure 4.10 
showed that the demethylation agent induced a dose-dependent increase in RNF180 
mRNA levels in NCI-H929 and OPM-2, but not in U266. Conversely, no significant 
change in GAPDH expression was observed. These data further indicated that 
methylation of the RNF180 promoter inhibits its expression in some M M cell lines. 
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Figure 4.10 Reactivation of RNF180 expression by 5-Aza-dC. The 
non-expressing M M cell lines (NCI-H929, OPM-2 and U266) were treated with 
various concentrations (1, 3, 5 and 10 uM) of 5-Aza-dC for 96 hours. Total RNA was 
extracted from untreated and treated cells for RT-PCR analysis. RNF180 mRNA 
expression was restored after treatment with increasing doses in NCI-H929 and 
OPM-2, but not in U266. PCR mixture with H2O served as a negative control. 
Amplification of GAPDH cDNA was carried out as an internal control for RNA 
integrity. 
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4.5.5 Methylation of RNFl80 in primary M M tumors 
We next examined whether hypermethylation of the RNFl 80 promoter could be 
detected in primary M M tumors. We used COBRA to evaluate RNFl80 promoter 
hypermethylation in 24 primary M M tumors and five normal PB lymphocyte 
samples. Our results showed that 15 out of 24 (63 %) primary M M tumors 
(CD138-positive cells) were methylated (Figure 4.11). Conversely, five normal PB 
lymphocyte samples were found to be unmethylated. To further evaluate the 
methylation status of each CpG sites, cloned bisulfite sequencing was performed for 
six primary M M samples. Our data showed that varying degrees of methylation (9-95 
%) were detected in the primary M M tumors [Figure 4.8(C)]. These data further 
confirmed the occurrence of RNFl 80 promoter hypermethylation in primary M M 
tumors. 
MM primary tumors N o r m a l PB 
IVI^rkci* “ •._••-•••丨丨丨 丨. 





M M M M U M U D U U U Methylation status 
Figure 4.11 A representative gel image of COBRA analysis of the RNFl80 
promoter in eight M M tumors and two normal PB lymphocyte samples. 
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CHAPTER 5 DISCUSSION 
5.1 Importance of methylation in MM 
Promoter hypermethylation-induced TSG inactivation has been widely reported 
in human cancers. To date, around 10 TSGs have been shown to be inactivated by 
aberrant methylation in MM. On the other hand, regional DNA hypomethylation can 
lead to ectopic gene activation. It has been found that some CGIs are normally 
methylated (Strichman-Almashanu et al., 2002), but become hypomethylated in 
cancer, leading to activation of nearby genes (Adoijan et al., 2002; 
Lacobuzio-Donahue et al., 2003). For instance, promoter hypomethylation-induced 
JAG2 overexpression appears to be an early event involving IL-6 production in M M 
pathogenesis (Houde et al., 2004; Takeuchi et al., 2005). Collectively, these findings 
suggest that in addition to genetic changes such as p53 and Ras mutation (Ortega et 
al” 2003; Rasmussen et al, 2005), chromosomal translocation at 14q32 (Taniwaki et 
al., 1994) and deletion at chromosome 13ql4 (Harrison et al, 2002; Liebisch et al, 
2005), epigenetic alterations by DNA methylation also plays a role in M M 
tumorigenesis. 
5.2 Genome-wide screening approach by MS.AP-PCR 
Previous methylation studies in M M mainly involved the use of gene-specific 
methylation analysis such as methylation-sensitive single nucleotide primer 
extension (MS-SNuPE), MS-PCR and COBRA. Although these techniques are 
widely used for detecting methylation changes at a specific locus, results are often 
limited to known methylation-regulated genes and no information on novel genes. 
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To reveal novel cancer-related genes regulated by CGIs methylation, we 
performed a genome-wide DNA methylation screening using MS.AP-PCR to scan 
methylation changes in M M and to identify aberrantly methylated genes. To the best 
o f our knowledge, this is the first global DNA methylation screening in MM. 
Other genome-wide scanning methods include RLGS (Kawai et al, 1993), 
MS-RDA (Ushijima et al, 1997)，MCA-RDA (Toyota et al, 1999) and D M H 
(Huang et al, 1999). They allow screening more than thousands of methylated 
sequences. For examples, RLGS can screen more than 2000 DNA sequences, 
whereas MS-RDA and MCA-RDA can screen lOMo ; DNA sequences. Nevertheless, 
these methods are technically more complex and require a large amount of DNA. 
Conversely, we selected MS.AP-PCR because it is a simple and reproducible 
method that has been used to identify novel cancer-related genes in tumors. For 
instance, this screening strategy has been employed to identify novel genes such as 
transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFF2), 
paired box gene 6 {PAX6), and pituitary tumor apoptosis gene {PTAG), that are 
hypermethylated in colon, bladder and pituitary adenomas (Liang et al., 2000; Salem 
et al, 2000; Bahar et al, 2004). 
Besides, another similar DNA fingerprinting technique called 
methylation-sensitive restriction fingerprinting analysis has been used to identify 
peroxisomal membrane protein 24kDa {PMP24) and endothelin receptor B (EDNRB), 
which are abnormally hypermethylated in prostate and nasopharyngeal carcinomas, 
respectively (Lo et al, 2002; Wu and Ho, 2004). These findings support the use of 
MS.AP-PCR as a global methylation screening approach. 
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5.3 Sample selection in MS.AP-PCR 
Sample preparation and selection are the first steps in genome-wide screening. 
To identify candidate methylation-regulated genes in MM, we used M M cell lines, 
primary M M tumors and normal PB lymphocytes in the screening and then 
compared the methylation patterns between tumor and normal samples. 
One of the advantages of applying M M cell lines is their homogeneous 
population, thus eliminating contamination of normal cells and providing distinct 
tumor methylation patterns. Besides, cell lines provide an unlimited amount of DNA 
for screening and downstream characterization. Nevertheless, the methylation 
patterns obtained from cell lines may differ from primary tumors because cell lines 
usually represent advanced cancer stages. Thus, some CGIs may be densely 
methylated in cell lines when compared with primary tumors. In addition, 
environmental stresses from cell cultures may yield artificial methylation patterns 
(Markl et al” 2001; Kaneda et al, 2002). Therefore, the findings must be validated in 
primary tumor samples. 
To prepare primary tumors for screening, it is important to have a homogeneous 
population of cells. Since primary M M samples are heterogeneous in cell types, the 
degree of methylation may be underestimated. To compensate this drawback, we 
isolated plasma cells from M M samples using magnetic cell sorting with a CD 138 
antibody, which is a specific cell-surface marker for plasma cells. 
Recent studies revealed that there are cell-type specific DNA methylation 
patterns (Futscher et al., 2002; Ohgane et al, 2002; Ohgane et al, 2005). It is better 
to select corresponding normal plasma cells as a normal control in the methylation 
analysis. However, normal plasma cells are very limited. To tackle this problem, 
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D N A from normal PB lymphocytes was used in this assay as they are generally 
accepted as a normal control for MM. 
5.4 Methylation patterns in MM 
Our present study provided the first estimation of genome-wide methylation 
changes in M M . The MS.AP-PCR scans the global CG-rich regions in the human 
genome and provides information on the methylation changes in individual samples. 
Analysis of the methylation patterns in normal PB lymphocytes revealed that 
nearly all (74/78; 95 %) evaluable sequences showed a consistent methylation status 
among the three individuals. This result is similar to that reported by other groups, 
who found little inter-individual variations in the methylation patterns among 
lymphocyte samples (Achten et al., 1991; Behn-Krappa et al., 1991). When 
compared with normal PB lymphocytes, the consistency of methylation patterns 
dramatically decreased in the M M cell lines (48/78; 62 %) and the primary M M 
tumors (39/78; 50 %). This heterogeneous methylation patterns may reflect different 
stages and characteristics within the tumor samples. 
Our results of methylation frequency showed that there was no significant 
difference between M M cell lines, primary M M samples and normal PB 
lymphocytes. This insignificant difference may be due to the small sample sizes in 
our studies. Conversely, studies in the colon demonstrated a significant reduction in 
5-methycytosine level in adenomas and adenocarcinomas when compared with 
normal and paired colonic mucosa (Feinberg et al, 1988). Hence, change of 
methylation frequency should not be excluded in MM. 
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Our data showed that M M cell lines exhibited a slightly higher frequency of 
both hypermethylation and hypomethylation when compared with the primary M M 
tumors. This phenomenon could be explained by the different stages of the M M 
specimens. M M cell lines often represent the late stage of tumor progression, while 
our primary M M represents some earlier stages. DNA hypermethylation may be 
accumulated during tumor progression. It has been demonstrated that the number of 
hypermethylated CpG islands tends to be higher in carcinomas than in adenomas 
(Bariol et al., 2003; Toyota et al, 1999) as well as in high-grade tumors (Toyota et 
al., 1999). Accordingly, studies have shown that hypermethylation of estrogen 
receptor in prostate cancer correlates with tumor progression. The overall 
methylation levels in prostate carcinomas and prostate cancer cell lines are higher 
than that of the benign prostatic hyperplasia samples (Li et al., 2000). Thus, it is 
likely that the degree of hypermethylations also increase as M M progresses. 
On the other hand, we found that the extent of DNA hypomethylation appeared 
to increase during M M progression. Previous studies have revealed that global DNA 
hypomethylation in breast carcinomas correlates significantly with disease stage 
(P=0.0009), tumor size (P=0.0026), and histologic grade (P=0.0097) (Scares et al, 
1999). However, the mechanisms governing these opposite phenomena 
(hypermethylation and hypomethylation) are not fully understood, but studies in 
colorectal (Bariol et al, 2003) and Wilm's tumors (Ehrlich et al, 2002) suggested 
that DNA hyper- and hypomethylation contribute independently to tumorigenesis. 
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5.5 Candidate genes selection strategies 
In this assay, we initially isolated 78 evaluable sequences which may be related 
to DNA methylation. To identify differential methylation changes in MM, 48 
evaluable sequences exhibiting potential differential methylation were selected. We 
then analyzed their genome localization. By UCSC BLAT analysis, we found that 24 
of 48 (50 %) candidate sequences were localized or adjacent to the defined CGIs 
(Gardiner-Garden and Frommer, 1987). We further selected those CGIs that 
corresponded to any mRNA or EST. Among the short list, 16 candidate sequences 
were identified as transcript-associated CGIs, in which 13 were identified as known 
genes and three were novel genes. Semi-quantitative RT-PCR was performed to 
examine the expression level of the 16 differentially methylated candidate genes. By 
this selection procedure, we identified two candidate genes ZHX2 and RNFl 80. They 
showed downregulated mRNA expression in some M M cell lines and were subjected 
to further study. In contrast, the other 14 candidates, which did not show a significant 
change in expression levels in the M M cell lines, ranked as a lower priority for 
further investigation. 
5.6 Zinc fingers and homeoboxes 2 
Our results demonstrated that aberrant hypermethylation of ZHX2 promoter 
correlated with its downregulated expression in M M cell lines. A recent gene 
expression profiling study showed that ZHX2 mRNA levels are downregulated in 
primary M M samples and this transcriptional repression is linked to poor survival 
(Harousseau et al, 2004). Consistently, we showed in the present study that ZHX2 
mRNA expression was downregulated or silenced in certain M M cell lines. 
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Treatment of ZHX2 methylated and non-expressing cells with 5-Aza-dC reactivated 
its expression, suggesting that the gene silencing is mediated by promoter 
hypermethylation. 
Our results showed that human ZHX2 belongs to the zinc-fingers and 
homeoboxes (ZHX) family, which consists of two other members, ZHX l and ZHX3. 
ZHX2 contains two Cys2-His2-type zinc-finger motifs, three Pro-Xaa2-Pro motifs, 
and five homeodomains (Barthelemy et al, 1996; Yamada et al, 1999a; Yamada et 
al., 1999b; Yamada et al, 2002; Kawata et al, 2003; Yamada et al, 2003). ZHX2 is 
ubiquitously expressed in human tissues and its amino acid sequence is conserved 
among human (100 %), mouse (40 %), and rat (40 %) (Kawata et al, 2003). 
It has been reported that ZHX2 interacts with a ubiquitous transcriptional 
activator (NF-YA) and represses the cdc25C promoter stimulated by NF-Y in 
Drosophila Schneider line 2 cells (Kawata et al, 2003). The cdc25C protein 
regulates cell cycle progression to the M phase (Gautier et al., 1991), suggesting that 
ZHX2 may participate in the regulation of a number of genes involved in cell cycle 
control (Kawata et al, 2003). This is supported by a negative correlation between the 
expression of ZHXl and some proliferation-associated genes including CCNBl, 
CCNB2, CCND2, CDC2, CDC25, T0P2A, TKl (Harousseau et al., 2004). 
The p53 TSG contains a proline-rich region that is composed of 15 amino acid 
residues and consists of two Pro-Xaa2-Pro motifs. This region is essential for the 
transcriptional repression of p53 (Walker and Levine 1996; Venot et al, 1998) by 
interacting with mSin3A (Zilfou et ai, 2001). mSinSA is an ubiquitous nuclear 
co-repressor that is associated with other transcriptional repressors such as Spl-like 
repressor (Ayer 1999; Ellenrieder et al., 2002). Since ZHX2 contains three 
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Pro-Xaa2-Pro motifs in its proline rich regions (Kawata et al, 2003), it has been 
suggested that ZHX2 may associate with mSinSA and involve in transcriptional 
repression of p53. 
Our findings showed that all (n=24) primary M M samples were unmethylated. 
Since, we examined the methylation status of three CpG sites in ZHX2 promoter 
region using COBRA, methylation changes outside the region may be omitted and 
underestimated. Methylation status of other regions or more CpG sites of the ZHX2 
promoter CGI should be evaluated. 
5.7 Ring finger protein 180 
Besides ZHX2, we found that aberrant methylation of the 5'CGI of a novel gene 
RNFl 80 occurred in 63 % primary M M tumors as well as some M M cell lines and 
this change was associated with transcriptional silencing. Treatment of RNFl80 
methylated and non-expressing cells with 5-Aza-dC reactivated its expression in 
certain M M cell lines, suggesting that promoter methylation of RNFl 80 silences its 
expression in MM. 
Information from Gene Ontology showed that the human RNFl 80 gene is 
located at chromosome 5ql2.3 and is highly conserved among mammals. Expression 
studies in human tissues revealed that RNFl 80 transcripts are highly expressed in 
kidney, soft tissue and vascular tissue, but weakly expressed in brain, eye, lung, 
pancreas, prostate, testis and uterus. In addition, the transcript is highly expressed 
during the juvenile development when compared with embryo and adult, implying 
that the expression of RNFl 80 is developmentally regulated. 
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The human RNF 180 gene encodes a hypothetical protein consisting of 416 
amino acid residues and shares 96，78, 75，75 and 68 % homology to the orangutan, 
chimpanzee, dog, mouse and cattle, respectively. RNF 180 protein is predicted to 
encode a RING-finger (Really Interesting New Gene) domain, which is a specialized 
type o f Zinc-finger o f 40 to 60 residues. It is defined by the ’ross-brace' moti f and 
binds two zinc ions, and thus potentially mediates protein-protein interactions. The 
function o f RNF 180 is unclear. However, various RING finger-containing proteins 
exhibit binding activity to E2 ubiquitin-conjugating enzymes, suggesting that 
RNF 180 may play a role in the ubiquitination pathway. 
Our present data showed that treatment of U266 cells with 5-Aza-dC could not 
restore RNF 180 mRNA expression, suggesting that other genetic or epigenetic 
mechanisms may be responsible for RNF 180 silencing in M M . These mechanisms 
may include allelic loss, missense mutation, or histone deacetylation. 
5.8 Limitations 
The detection of methylation changes may serve as a molecular marker for early 
detections and disease monitoring of M M . However, we could not find any statistical 
significance from MS.AP-PCR results. The number of samples (n<5) per each group 
was small. The small sample size may not allow analyzing the correlation between 
methylation changes and their clinical parameters. Therefore, increase the sample 
size would facilitate the analysis of the methylation changes. 
The yield of candidates identified by MS.AP-PCR was low after validation. 
Hal f (24/48) of the candidate sequences were localized outside CGIs. Since many 
84 
CG-rich repetitive sequences such as long interspersed nuclear elements (LINEs), 
short interspersed nuclear elements (SINEs) and Alu repetitive sequences exist in the 
human genome. They might be amplified by CG-rich arbitrary primers. 
In addition, CGIs outside 5' promoter region were identified in MS.AP-PCR. 
Since not all CGIs are localized to the 5' promoter region, methylation of these CGIs 
usually may not regulate their gene transcription (Wutz et aL, 1997; Gonzalgo et al., 
1998). Nevertheless, this problem is not restricted to MS.AP-PCR. Other methylation 
screening approaches also identified the CpG-rich sequences outside 5' promoter 
region (Davies 2002; Liang et al, 2002). Recent studies revealed that methylation of 
transcribed regions and regions near regulatory elements also involve in the gene 
expression (Aranyi et al, 2005; Meng et al., 2003). Therefore, we did not limit the 
selection to 5'CGIs and isolated transcript-associated CGIs during validation. 
COBRA and bisulfite sequencing were performed in the candidate gene 
methylation analysis. Though COBRA provides a simple and rapid scanning of 
methylation status, it may omit and underestimate methylation change outside the 
restriction enzyme recognition sites. Therefore, more than one restriction enzyme can 
be included for COBRA to increase the number of CpG sites being detected. Cloned 
bisulfite sequencing is labour intensive and more tedious, but it provides information 
on the methylation status of every cytosine residue within the target sequence. Hence, 
using both methods can facilitate a rapid and promising methylation analysis. 
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CHAPTER 6 CONCLUSION 
Two candidate cancer-related genes, ZHX2 and RNF 180, have been identified 
by MS.AP-PCR. This approach enables identification of novel cancer-related genes 
in M M without the requirement of prior sequence information. Thus, MS.AP-PCR 
may be exploited to identify targets as biomarkers for the cancer prevention, 
diagnosis and treatment. 
For the candidate gene ZHX2, aberrant promoter methylation was detected in 
M M cell lines. Transcriptional silencing or down-regulation was demonstrated in 
methylated cells, and reactivation occurred in the non-expressing cells after 
demethylation treatment. Combined our results with the reduced gene expression of 
ZHX2 in M M by other group (Harousseau et al, 2004); these findings further support 
the involvement oiZHXl gene in M M malignancy. 
In addition to ZHX2, we found that aberrant methylation of the 5'CGI of a novel 
gene RNF 180 occurred in 63 % primary M M tumors and certain M M cell lines. This 
epigenetic change was associated with its transcriptional inactivation. Treatment of 
demethylating agent (5-Aza-dC) restored some non-expressing M M cell lines with 
methylated alleles. Taken together, the aberrant DNA methylation of RNF 180 may 
contribute to the M M tumorigenesis. 
Although we have identified these two putative cancer-related genes in MM, 
their potential biological functions in human cancer pathogenesis remain to be 
elucidated. Functional characterization on the role of cell proliferation, apoptosis or 
other biological functions provides more information to understand the pathogenesis 
of M M . 
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